var title_f22_42_23200="Wagner 4 foot ulcer";
var content_f22_42_23200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F63780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F63780&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Wagner grade 4 ulcer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 241px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Foot from a diabetic patient with a Wagner grade 4 ulcer that extends to the deep layers with signs of local infection, cellulitis, and necrosis. This lesion healed completely after an extensive hospital stay involving excision of necrotic tissue but no amputation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David McCulloch, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23200=[""].join("\n");
var outline_f22_42_23200=null;
var title_f22_42_23201="Ureterocele hydronephrosis";
var content_f22_42_23201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F79559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F79559&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 556px\">",
"   <div class=\"ttl\">",
"    Ureteroceles in a right duplex collecting system",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 536px; height: 306px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A ureterocele is a cystic dilation of a segment of the ureter contained within the bladder wall (ie, intravesical ureter). Intravesical ureteroceles are contained entirely within the bladder. Ectopic ureteroceles are partially situated at the bladder neck or urethra.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23201=[""].join("\n");
var outline_f22_42_23201=null;
var title_f22_42_23202="Cyclosporine (ophthalmic): Pediatric drug information";
var content_f22_42_23202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclosporine (ophthalmic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?14/26/14756?source=see_link\">",
"    see \"Cyclosporine (ophthalmic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?6/52/6980?source=see_link\">",
"    see \"Cyclosporine (ophthalmic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8012533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Restasis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F14959798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Restasis&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10825664\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immunosuppressant Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10825670\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/26/14756?source=see_link\">",
"      see \"Cyclosporine (ophthalmic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;16 years and Adults: Ophthalmic: Instill one drop in affected eye(s) every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8012680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Emulsion, ophthalmic [drops, preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Restasis&reg;: 0.05% (0.4 mL) [contains castor oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8012548\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10825671\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Invert vial prior to use to obtain a uniform emulsion. Avoid contact of vial tip with skin or eye; remove contact lenses prior to administration; lenses may be inserted 15 minutes after instillation. May be used with artificial tears; separate administration by at least 15 minutes.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10825668\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at room temperature; protect from light.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10825665\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increase tear production in patients with moderate to severe keratoconjunctivitis sicca-associated ocular inflammation",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8012532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       CycloSPORINE may be confused with cyclophosphamide, Cyklokapron&reg;, cycloSERINE",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8012586\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     Ocular: Blurred vision, burning, conjunctival hyperemia, discharge, epiphora, eye pain, foreign body sensation, pruritus, stinging, visual disturbance",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10825666\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cyclosporine or any component; active ocular infections",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8012590\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8029321\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10923624\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed following the use of oral cyclosporine in animal reproduction studies when using doses that were approximately 300,000 times greater than a human ophthalmic dose (assuming complete absorption).",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10825669\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibition of production and release of interleukin II and inhibits interleukin II-induced activation of resting T lymphocytes",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15961 Version 24.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.80.101-C15F01F966-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23202=[""].join("\n");
var outline_f22_42_23202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012533\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14959798\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825664\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825670\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012680\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012548\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825671\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825668\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825665\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012532\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012586\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825666\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299110\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8012590\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8029321\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10923624\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10825669\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15961\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15961|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?14/26/14756?source=related_link\">",
"      Cyclosporine (ophthalmic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?6/52/6980?source=related_link\">",
"      Cyclosporine (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?30/8/30858?source=related_link\">",
"      Cyclosporine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/28/40390?source=related_link\">",
"      Cyclosporine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?35/55/36729?source=related_link\">",
"      Cyclosporine (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_42_23203="Ultrasound of the tibialis anterior";
var content_f22_42_23203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F68360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F68360&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Ultrasound of the tibialis anterior muscle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 329px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These are axial (left) and sagittal (right) images of the tibialis anterior muscle. Note the distinction of the muscle from the thin layer of subcutaneous tissue marked by arrows. The aponeurosis (A) stands out from the rest of the muscle in both images. The sagittal image (right) shows the bipennate attachments of the muscle fibrous tissue, which joins the aponeurosis at a distinct angle of pennation. The bone edge above the tibia (T) is bright and crisply defined.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Francis O Walker, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23203=[""].join("\n");
var outline_f22_42_23203=null;
var title_f22_42_23204="Icodextrin: Patient drug information";
var content_f22_42_23204=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Icodextrin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=see_link\">",
"     see \"Icodextrin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F181621\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Extraneal",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10019129\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10019131\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691298",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used during dialysis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10019130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702286",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to icodextrin, cornstarch, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2703743",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have glycogen storage disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10019135\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high blood sugar (diabetes), talk with your doctor. Make sure that this drug will not get in the way of your blood sugar tests.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high calcium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697294",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low magnesium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697297",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have low potassium levels, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697300",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have lung disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697332",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have poor eating habits, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had recent stomach surgery or any stomach problems, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10019136\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697983",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cough.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10019138\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698629",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Cloudy drained dialysis fluid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699091",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling of belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10019133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694871",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow what your doctor has told you to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10019134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10019139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699169",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use if the solution is cloudy, leaking, or has particles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10019140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11766 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-89.218.100.194-EFEE8658EB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23204=[""].join("\n");
var outline_f22_42_23204=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F181621\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019129\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019131\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019130\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019135\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019136\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019138\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019133\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019134\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019139\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10019140\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?43/36/44612?source=related_link\">",
"      Icodextrin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_42_23205="Steroid injection PI";
var content_f22_42_23205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F68653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F68653&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralesional corticosteroids",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Triamcinolone is injected intradermally on the scalp in areas affected by alopecia areata.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew G Messenger, MD, FRCP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23205=[""].join("\n");
var outline_f22_42_23205=null;
var title_f22_42_23206="Autoimmune chronic hepatitis after immunosupportive therapy";
var content_f22_42_23206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54752&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Autoimmune chronic hepatitis after immunosupportive therapy (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 275px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The liver biopsy is normal after 16 months of immunosupportive therapy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23206=[""].join("\n");
var outline_f22_42_23206=null;
var title_f22_42_23207="Idiopathic restrictive cardiomyopathy";
var content_f22_42_23207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Idiopathic restrictive cardiomyopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23207/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23207/contributors\">",
"     Naser M Ammash, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23207/contributors\">",
"     A Jamil Tajik, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23207/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23207/contributors\">",
"     William J McKenna, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23207/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23207/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/42/23207/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     DEFINITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary cardiomyopathies are classified into three general categories depending upon their respective disorders of structure and function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link\">",
"     \"Definition and classification of the cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Dilated",
"     </li>",
"     <li>",
"      Hypertrophic",
"     </li>",
"     <li>",
"      Restrictive",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Restrictive cardiomyopathy has distinct morphologic and hemodynamic characteristics that separate it from the more common dilated and hypertrophic cardiomyopathies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A nondilated ventricle with normal wall thickness",
"     </li>",
"     <li>",
"      Ventricular walls that are rigid, resulting in severe diastolic dysfunction and restrictive filling that produces elevated filling pressures and dilated atria",
"     </li>",
"     <li>",
"      Normal left ventricular systolic function in the vast majority of patients",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Restrictive cardiomyopathy has some resemblance to constrictive pericarditis as it primarily causes diastolic dysfunction resulting in abnormal ventricular filling. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY AND DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic or primary restrictive cardiomyopathy is an uncommon disorder that is manifested by characteristic morphologic and physiologic changes in the absence of any identifiable cause. It is a diagnosis of exclusion because restrictive physiology is also seen in patients with a number of other disorders, including several systemic conditions. These disorders, most of which are discussed in detail elsewhere, include the following&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/3\">",
"     3",
"    </a>",
"    ]: (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=see_link&amp;anchor=H8#H8\">",
"     \"Definition and classification of the cardiomyopathies\", section on 'Restrictive cardiomyopathy'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Noninfiltrative disorders include familial cardiomyopathy (see",
"      <a class=\"local\" href=\"#H3\">",
"       'Familial disease'",
"      </a>",
"      below), hypertrophic cardiomyopathy, scleroderma, pseudoxanthoma elasticum, and diabetic cardiomyopathy. In addition, secondary restrictive physiology can develop during the advanced stages of dilated, hypertensive, or ischemic heart disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/3-5\">",
"       3-5",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link\">",
"       \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=see_link&amp;anchor=H18#H18\">",
"       \"Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults\", section on 'Myocardial disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=see_link\">",
"       \"Heart failure in diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infiltrative disorders include amyloidosis, sarcoidosis, Gaucher disease, Hurler syndrome, and fatty infiltration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"       \"Cardiac sarcoidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=see_link&amp;anchor=H5#H5\">",
"       \"Clinical features and diagnosis of the mucopolysaccharidoses\", section on 'Hurler syndrome'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Storage diseases include hemochromatosis, Fabry disease, and glycogen storage disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=see_link&amp;anchor=H14#H14\">",
"       \"Clinical manifestations of hereditary hemochromatosis\", section on 'Heart disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=see_link\">",
"       \"Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other disorders include endomyocardial fibrosis, radiation, chemotherapy, hypereosinophilic syndrome, carcinoid heart disease, metastatic cancers, and drugs causing fibrous endocarditis (serotonin, methysergide,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/20/23877?source=see_link\">",
"       ergotamine",
"      </a>",
"      , mercurial agents,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"       busulfan",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=see_link\">",
"       \"Endomyocardial fibrosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"       \"Cardiotoxicity of radiation therapy for malignancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=see_link\">",
"       \"Cardiotoxicity of anthracycline-like chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=see_link\">",
"       \"Cardiotoxicity of nonanthracycline cancer chemotherapy agents\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link&amp;anchor=H15#H15\">",
"       \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\", section on 'Cardiac disease'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=see_link\">",
"       \"Carcinoid heart disease\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Endomyocardial diseases (eg, endomyocardial fibrosis, hypereosinophilic syndrome) are characterized by endomyocardial scarring that usually affects one or both ventricles and restricts filling. Involvement of the atrioventricular valves is common but the outflow tracts are spared. &nbsp;",
"      <br/>",
"      <br/>",
"      Radiation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      drug (eg, anthracycline) toxicity can cause a restrictive cardiomyopathy or dilated cardiomyopathy. Endomyocardial fibrosis has been identified in some cases.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Restrictive cardiomyopathy must be distinguished from constrictive pericarditis, which causes a similar impairment in ventricular filling. While details of the clinical history may sometimes be diagnostic, this distinction can require careful echocardiographic and hemodynamic assessment, pericardial imaging, and even endomyocardial biopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Familial disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familial restrictive cardiomyopathies not related to amyloidosis are exceedingly rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=see_link\">",
"     \"Inherited syndromes associated with cardiac disease\"",
"    </a>",
"    .) Three reports of familial disease suggest that primary restrictive cardiomyopathy can be transmitted as an autosomal dominant trait [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The natural history, as reported in one five generation family, is of symptomatic disease that develops after the third decade of life, with an insidious downhill course [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/9\">",
"     9",
"    </a>",
"    ]. Individuals who survive into the fifth decade develop a progressive nonwasting skeletal myopathy. Neither the chromosome location(s) nor the responsible disease gene(s) have been identified.",
"   </p>",
"   <p>",
"    Several observations suggest that familial restrictive cardiomyopathy may be part of the spectrum of familial hypertrophic cardiomyopathy (HCM) in which there is different phenotypic expression of the same genetic disease. The supportive data are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=see_link&amp;anchor=H4#H4\">",
"     \"Natural history of hypertrophic cardiomyopathy\", section on 'Relation to restrictive cardiomyopathy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic restrictive cardiomyopathy can present at any age, but its incidence is increased in elderly adults; it is more common in older women than men [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/5\">",
"     5",
"    </a>",
"    ]. Affected patients have symptoms and signs of both pulmonary and systemic congestion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The most common symptoms include dyspnea, peripheral edema, palpitations, fatigue, weakness, and exercise intolerance due to failure of the cardiac output to increase with an increase in heart rate without further compromising ventricular filling. In advanced cases, there may be a marked elevation in central venous pressure, resulting in hepatosplenomegaly, ascites, and anasarca.",
"   </p>",
"   <p>",
"    The cardiovascular examination is often indistinguishable from that of constrictive pericarditis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The pulse can either be normal or convey evidence of low stroke volume with low amplitude and tachycardia.",
"     </li>",
"     <li>",
"      The jugular venous pressure is generally elevated with prominent y descent; however, these changes may not be obvious in patients with mild disease. An inspiratory increase in venous pressure, known as Kussmaul's sign, may be seen. This finding is thought to be due at least in part to increased resistance to right atrial filling during inspiration. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=see_link\">",
"       \"Examination of the jugular venous pulse\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The left ventricular impulse is usually normal. A nonpalpable impulse increases the suspicion for constrictive pericarditis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=see_link\">",
"       \"Examination of the precordial pulsation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The first and second heart sounds are usually normal. A third heart sound (S3 gallop) is frequently present because of the abrupt cessation of the rapid ventricular filling. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=see_link\">",
"       \"Auscultation of heart sounds\"",
"      </a>",
"      .) Soft systolic murmurs of functional mitral and tricuspid valve regurgitation are also common. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=see_link\">",
"       \"Auscultation of cardiac murmurs\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Electrocardiogram",
"    </span>",
"    &nbsp;&mdash;&nbsp;Electrocardiographic abnormalities in idiopathic restrictive cardiomyopathy are nonspecific and include atrial fibrillation, nonspecific ST-T wave abnormalities, premature atrial and ventricular beats, atrioventricular block, and intraventricular conduction delay. These abnormalities can also be seen in patients with constrictive pericarditis or infiltrative myocardial diseases such as amyloidosis and sarcoidosis. The QRS voltage is typically normal in idiopathic restrictive cardiomyopathy, not low as in constrictive pericarditis or amyloidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;The chest x-ray usually demonstrates cardiomegaly secondary to significant atrial enlargement with pulmonary venous congestion and pleural effusions. Pericardial calcification should raise the suspicion for constrictive pericarditis (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64005 \" href=\"UTD.htm?12/18/12578\">",
"     image 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restrictive cardiomyopathy has some resemblance to constrictive pericarditis as it primarily causes diastolic dysfunction resulting in abnormal ventricular filling. The history may be of value in suggesting one of these disorders:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prior history of pericarditis, a systemic disease that affects the pericardium (eg, tuberculosis, connective tissue disease, malignancy), trauma, or cardiac surgery makes the diagnosis of constrictive pericarditis more likely. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=see_link\">",
"       \"Etiology of pericardial disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      A history of an infiltrative disease that may involve the heart muscle (eg, amyloidosis or sarcoidosis) favors the diagnosis of restrictive cardiomyopathy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=see_link\">",
"       \"Clinical manifestations and diagnosis of amyloid cardiomyopathy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=see_link\">",
"       \"Cardiac sarcoidosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    On the other hand, prior mantle radiation can result in both pericardial restriction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    restrictive cardiomyopathy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A number of techniques are available for establishing the correct diagnosis, including echocardiography, magnetic resonance imaging, computed tomography, and endomyocardial biopsy. The use of these tests is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=see_link\">",
"     \"Differentiating constrictive pericarditis and restrictive cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=see_link\">",
"     \"Echocardiographic recognition of cardiomyopathies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Plasma BNP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma concentrations of brain natriuretic peptide (BNP) are increased in patients with left ventricular dysfunction; as a result, plasma BNP has been used in the diagnosis of dyspnea and to assess the efficacy of therapy and estimate prognosis in patients with heart failure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"     \"Natriuretic peptide measurement in heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among patients with restrictive cardiomyopathy, BNP is released in response to left ventricular dysfunction and wall stretch. However, wall stretch is limited in constrictive pericarditis by the thickened stiff pericardium. These physiologic differences suggest that measurement of plasma BNP might have value in distinguishing between these two disorders.",
"   </p>",
"   <p>",
"    An initial report of six patients with constrictive pericarditis and five with restrictive cardiomyopathy diagnosed by hemodynamic assessment provided support for the value of plasma BNP [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/12\">",
"     12",
"    </a>",
"    ]. Plasma BNP was markedly elevated in patients with restrictive cardiomyopathy and just above normal in those with constrictive pericarditis (825 versus 128",
"    <span class=\"nowrap\">",
"     pg/mL;",
"    </span>",
"    normal &le;100",
"    <span class=\"nowrap\">",
"     pg/mL).",
"    </span>",
"    These intriguing observations need to be confirmed in a larger number of patients to determine the accuracy of BNP testing. However, because the physiologic rationale is strong, we recommend measurement of plasma BNP early in the evaluation of patients with suspected restrictive cardiomyopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Endomyocardial biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endomyocardial biopsy is performed in patients with suspected restrictive cardiomyopathy to exclude specific heart muscle disease such as amyloidosis, sarcoidosis, and hemochromatosis. This procedure is highly specific for excluding specific heart muscle diseases and myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/3,13-15\">",
"     3,13-15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=see_link\">",
"     \"Endomyocardial biopsy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In idiopathic restrictive cardiomyopathy, light microscopic examination often demonstrates nonspecific patchy endocardial and interstitial fibrosis with increased collagen deposition, myocellular hypertrophy without any myofiber necrosis or disarray, and without lymphocytic or eosinophilic infiltration, or amyloid or iron deposition [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/3,13,14\">",
"     3,13,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific therapy for idiopathic restrictive cardiomyopathy, whereas therapy of certain underlying diseases (eg, sarcoidosis, hemochromatosis) may be beneficial in patients with secondary restrictive cardiomyopathy.",
"   </p>",
"   <p>",
"    Treatment of the cardiac disease is aimed at reducing pulmonary and systemic congestion. This is best achieved by lowering the venous pressure, controlling heart rate, increasing filling time, maintenance of atrial contractions, correction of atrioventricular conduction disturbances, and avoidance of anemia, nutritional deficiency, calcium overload, and electrolyte imbalance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Loop diuretics, usually in low to medium doses, are given to relieve systemic and pulmonary venous congestion. However, patients with restrictive cardiomyopathy require high filling pressure to maintain their cardiac output. Thus, systemic perfusion, as assessed by physical examination and measurement of the blood urea nitrogen and serum creatinine concentration, should be carefully monitored. An otherwise unexplained elevation in the latter tests is indicative of hypoperfusion and further diuresis should be avoided.",
"     </li>",
"     <li>",
"      Rate-lowering calcium channel blockers (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      ) may have a therapeutic role by improving diastolic function and, via rate control, by increasing filling time. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=see_link\">",
"       \"Treatment and prognosis of diastolic heart failure\"",
"      </a>",
"      .) This is based upon the observation that idiopathic restrictive cardiomyopathy may be a biochemical abnormality of the energy-dependent rapid filling phase of cardiac relaxation, a process that is rate-dependent and requires pumping of the calcium out of the cytosol and restoration of the sodium and calcium gradients across the sarcolemma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30313?source=see_link\">",
"       \"Cellular mechanisms of diastolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Beta blockers may also be of benefit. They may act by suppressing the long-term deleterious consequences of compensatory sympathetic stimulation on myocyte function, by controlling the heart rate (which increases filling time), and by improving ventricular relaxation.",
"     </li>",
"     <li>",
"      Angiotensin-converting enzyme (ACE) inhibitors",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angiotensin II receptor blockers appear to improve diastolic filling by counteracting the compensatory neurohormonal changes associated with heart failure. Although ACE inhibitors have proven benefits in patients with heart failure due to systolic dysfunction, their role in patients with diastolic dysfunction who have normal ventricular size and function is uncertain. In at least some forms of diastolic dysfunction, they reduce myocardial stiffness by decreasing myocardial angiotensin II production [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/16\">",
"       16",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=see_link\">",
"       \"ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=see_link\">",
"       \"Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/27/29113?source=see_link\">",
"       Digoxin",
"      </a>",
"      increases intracellular calcium and therefore should be used with",
"      <strong>",
"       caution",
"      </strong>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=see_link\">",
"       \"Use of digoxin in heart failure due to systolic dysfunction\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Maintenance of properly timed atrial contraction improves ventricular filling. Thus, permanent dual chamber pacemaker is indicated in the presence of advanced atrioventricular block. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=see_link\">",
"       \"Indications for permanent cardiac pacing\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients in atrial fibrillation should be anticoagulated to decrease the risk of thromboembolism. Rate control is also warranted, usually with a calcium channel blocker or beta blocker. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=see_link\">",
"       \"Control of ventricular rate in atrial fibrillation: Pharmacologic therapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cardiac transplantation should be performed in eligible patients with intractable heart failure. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=see_link\">",
"       \"Indications and contraindications for cardiac transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Investigational treatments, including gene therapy aiming at enhancing sarcoplasmic calcium transport, have shown therapeutic promise in animal models of heart failure and in myopathic cardiomyocytes. Such therapies may be of potential benefit for patients with restrictive cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advanced diastolic dysfunction (grade III to IV restrictive physiology) is associated with a poor prognosis in secondary restrictive cardiomyopathy such as cardiac amyloidosis.",
"   </p>",
"   <p>",
"    Patients with symptomatic idiopathic restrictive cardiomyopathy also appear to have a poor prognosis. In our series of 94 such patients who were followed for a mean of 68 months, estimated overall survival was significantly lower than expected for an age and gender matched group: 64 versus 85 percent at five years and 37 versus 70 percent at 10 years (",
"    <a class=\"graphic graphic_figure graphicRef50778 \" href=\"UTD.htm?25/21/25949\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately two-thirds of deaths were cardiovascular, primarily due to heart failure, sudden death, arrhythmia, or a cerebrovascular accident. Among the survivors, 28, 46, and 17 percent were in New York Heart Association class I, II, and III, respectively (",
"    <a class=\"graphic graphic_table graphicRef52683 \" href=\"UTD.htm?3/2/3117\">",
"     table 1",
"    </a>",
"    ), and 9 percent had undergone cardiac transplantation.",
"   </p>",
"   <p>",
"    Adverse risk factors for survival in our series included male gender, age greater than 70, each increment in functional class, and left atrial diameter &gt;60 mm. Survival was not related to the presence of atrial fibrillation, left ventricular systolic dysfunction, or findings on myocardial biopsy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18583167\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Idiopathic or primary restrictive cardiomyopathy is an uncommon disorder that is manifested by characteristic morphologic and physiologic changes in the absence of any identifiable cause. It is a diagnosis of exclusion because restrictive physiology is also seen in patients with a number of systemic disorders. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Etiology and differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Familial restrictive cardiomyopathies not related to amyloidosis are exceedingly rare. Several observations suggest that familial restrictive cardiomyopathy may be part of the spectrum of familial hypertrophic cardiomyopathy (HCM) in which there is different phenotypic expression of the same genetic disease. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Familial disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Idiopathic restrictive cardiomyopathy can present at any age, but its incidence is increased in elderly adults; it is more common in older women than men [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23207/abstract/5\">",
"       5",
"      </a>",
"      ]. Affected patients have symptoms and signs of both pulmonary and systemic congestion. The cardiovascular examination is often indistinguishable from that of constrictive pericarditis. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical Presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Endomyocardial biopsy is performed in patients with suspected restrictive cardiomyopathy to exclude specific heart muscle disease such as amyloidosis, sarcoidosis, and hemochromatosis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Endomyocardial biopsy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There is no specific therapy for idiopathic restrictive cardiomyopathy, whereas therapy of certain underlying diseases (eg, sarcoidosis, hemochromatosis) may be beneficial in patients with secondary restrictive cardiomyopathy. Treatment is aimed at reducing pulmonary and systemic congestion. This is best achieved by lowering the venous pressure, controlling heart rate, increasing filling time, maintenance of atrial contractions, correction of atrioventricular conduction disturbances, and avoidance of anemia or electrolyte imbalance. Cardiac transplantation should be performed in patients with intractable heart failure. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although data are limited, patients with symptomatic idiopathic restrictive cardiomyopathy appear to have poor prognosis. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/1\">",
"      Report of the WHO/ISFC task force on the definition and classification of cardiomyopathies. Br Heart J 1980; 44:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/2\">",
"      Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of cardiomyopathies. Circulation 1996; 93:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/3\">",
"      Kushwaha SS, Fallon JT, Fuster V. Restrictive cardiomyopathy. N Engl J Med 1997; 336:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/4\">",
"      Benotti JR, Grossman W, Cohn PF. Clinical profile of restrictive cardiomyopathy. Circulation 1980; 61:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/5\">",
"      Ammash NM, Seward JB, Bailey KR, et al. Clinical profile and outcome of idiopathic restrictive cardiomyopathy. Circulation 2000; 101:2490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/6\">",
"      Hatle LK, Appleton CP, Popp RL. Differentiation of constrictive pericarditis and restrictive cardiomyopathy by Doppler echocardiography. Circulation 1989; 79:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/7\">",
"      Palka P, Lange A, Donnelly JE, Nihoyannopoulos P. Differentiation between restrictive cardiomyopathy and constrictive pericarditis by early diastolic doppler myocardial velocity gradient at the posterior wall. Circulation 2000; 102:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/8\">",
"      Angelini A, Calzolari V, Thiene G, et al. Morphologic spectrum of primary restrictive cardiomyopathy. Am J Cardiol 1997; 80:1046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/9\">",
"      Fitzpatrick AP, Shapiro LM, Rickards AF, Poole-Wilson PA. Familial restrictive cardiomyopathy with atrioventricular block and skeletal myopathy. Br Heart J 1990; 63:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/10\">",
"      Mogensen J, Kubo T, Duque M, et al. Idiopathic restrictive cardiomyopathy is part of the clinical expression of cardiac troponin I mutations. J Clin Invest 2003; 111:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/11\">",
"      Carroll JD, Gaasch WH, McAdam KP. Amyloid cardiomyopathy: characterization by a distinctive voltage/mass relation. Am J Cardiol 1982; 49:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/12\">",
"      Leya FS, Arab D, Joyal D, et al. The efficacy of brain natriuretic peptide levels in differentiating constrictive pericarditis from restrictive cardiomyopathy. J Am Coll Cardiol 2005; 45:1900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/13\">",
"      Siegel RJ, Shah PK, Fishbein MC. Idiopathic restrictive cardiomyopathy. Circulation 1984; 70:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/14\">",
"      Hosenpud JD, Niles NR. Clinical, hemodynamic and endomyocardial biopsy findings in idiopathic restrictive cardiomyopathy. West J Med 1986; 144:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/15\">",
"      Schoenfeld MH, Supple EW, Dec GW Jr, et al. Restrictive cardiomyopathy versus constrictive pericarditis: role of endomyocardial biopsy in avoiding unnecessary thoracotomy. Circulation 1987; 75:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/16\">",
"      Friedrich SP, Lorell BH, Rousseau MF, et al. Intracardiac angiotensin-converting enzyme inhibition improves diastolic function in patients with left ventricular hypertrophy due to aortic stenosis. Circulation 1994; 90:2761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23207/abstract/17\">",
"      Hajjar RJ, del Monte F, Matsui T, Rosenzweig A. Prospects for gene therapy for heart failure. Circ Res 2000; 86:616.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4918 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23207=[""].join("\n");
var outline_f22_42_23207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18583167\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      DEFINITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY AND DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Familial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Electrocardiogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Plasma BNP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18583167\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/4918\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4918|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?12/18/12578\" title=\"diagnostic image 1\">",
"      Lateral CXR showing pericardial calcium",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4918|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?25/21/25949\" title=\"figure 1\">",
"      Survival restrictive CM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/4918|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?3/2/3117\" title=\"table 1\">",
"      Methods to assess cardiovascular disability",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16090?source=related_link\">",
"      ACE inhibitors in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/39/2680?source=related_link\">",
"      Angiotensin II receptor blockers in heart failure due to systolic dysfunction: Therapeutic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/37/26202?source=related_link\">",
"      Auscultation of cardiac murmurs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/56/22410?source=related_link\">",
"      Auscultation of heart sounds",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/45/17111?source=related_link\">",
"      Cardiac manifestations of Fabry disease and screening in patients with left ventricular hypertrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/19/17722?source=related_link\">",
"      Cardiac sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/46/41706?source=related_link\">",
"      Cardiotoxicity of anthracycline-like chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/12/40138?source=related_link\">",
"      Cardiotoxicity of nonanthracycline cancer chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/38/30313?source=related_link\">",
"      Cellular mechanisms of diastolic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/6/7274?source=related_link\">",
"      Clinical features and diagnosis of the mucopolysaccharidoses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/10/23722?source=related_link\">",
"      Clinical manifestations and diagnosis of amyloid cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/60/28617?source=related_link\">",
"      Clinical manifestations of hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/50/12074?source=related_link\">",
"      Control of ventricular rate in atrial fibrillation: Pharmacologic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/3/30777?source=related_link\">",
"      Definition and classification of the cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29752?source=related_link\">",
"      Differentiating constrictive pericarditis and restrictive cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/12/15562?source=related_link\">",
"      Echocardiographic recognition of cardiomyopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7592?source=related_link\">",
"      Endomyocardial biopsy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/32/40454?source=related_link\">",
"      Endomyocardial fibrosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/43/30392?source=related_link\">",
"      Etiology of pericardial disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/59/33719?source=related_link\">",
"      Examination of the jugular venous pulse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/43/9909?source=related_link\">",
"      Examination of the precordial pulsation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/57/28569?source=related_link\">",
"      Heart failure in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/31/34297?source=related_link\">",
"      Indications and contraindications for cardiac transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/52/27463?source=related_link\">",
"      Indications for permanent cardiac pacing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/20/1351?source=related_link\">",
"      Inherited syndromes associated with cardiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/4/32841?source=related_link\">",
"      Natural history of hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=related_link\">",
"      Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29224?source=related_link\">",
"      Overview of the clinical manifestations of systemic sclerosis (scleroderma) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7018?source=related_link\">",
"      Treatment and prognosis of diastolic heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/4/18504?source=related_link\">",
"      Use of digoxin in heart failure due to systolic dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_42_23208="Pharmacologic use of glucocorticoids";
var content_f22_42_23208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pharmacologic use of glucocorticoids",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23208/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23208/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23208/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23208/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23208/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23208/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/42/23208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 30, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Natural and synthetic glucocorticoids are used in both endocrine and nonendocrine disorders.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In endocrine practice, glucocorticoids are given only to establish the diagnosis and cause of Cushing's syndrome and for treatment of adrenal insufficiency and congenital adrenal hyperplasia.",
"     </li>",
"     <li>",
"      Pharmacologic doses of glucocorticoids are used to treat patients with inflammatory, allergic, immunological disorders. If chronic, this supra-physiologic therapy has many adverse effects, ranging from suppression of the hypothalamic-pituitary-adrenal axis and Cushing's syndrome to infections and changes in mental status. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A number of factors that influence both the therapeutic and adverse effects of glucocorticoids will be reviewed here, including the biologic potency, pharmacokinetic properties of the glucocorticoid, daily dose, timing of doses during the day, individual differences in steroid metabolism, and the duration of treatment (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Other issues, including the determinants of steroid dosing and the approach to glucocorticoid withdrawal to prevent adrenal insufficiency and minimize the likelihood of recurrent activity of the underlying disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31703?source=see_link\">",
"     \"Determinants of glucocorticoid dosing\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     STRUCTURES OF COMMON SYNTHETIC STEROIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical modification of natural steroids in the 1950s revealed a number of structural features essential for biological activity. The delta-4,3-keto-11-beta,17-alpha,21-trihydroxyl configuration (",
"    <a class=\"graphic graphic_figure graphicRef53204 \" href=\"UTD.htm?11/19/11582\">",
"     figure 1",
"    </a>",
"    ) is required for glucocorticoid activity and is present in all natural and synthetic glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The introduction of a double bond between the 1 and 2 positions of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (cortisol) yields",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    (delta-1-hydrocortisone), which has about four times more glucocorticoid activity than cortisol (",
"    <a class=\"graphic graphic_figure graphicRef74705 \" href=\"UTD.htm?39/44/40655\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the cortisol in serum is bound to proteins, primarily corticosteroid-binding globulin (CBG) and albumin. In addition, much of the biologically available cortisol may be bound to erythrocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because they have little or no affinity for CBG, synthetic steroids other than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    either bind weakly to albumin (two-thirds) or circulate as free steroid (one-third) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Plasma disappearance half-life",
"    </span>",
"    &nbsp;&mdash;&nbsp;The half-lives of synthetic glucocorticoids are generally longer than that of cortisol, which is about 80 minutes at concentrations within the binding capacity of CBG (ie, less than about 25",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    [690",
"    <span class=\"nowrap\">",
"     nmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The half-lives of the synthetic steroids range from about one hour for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    to over four hours for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , with considerable interindividual variation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]; clearance in older adults may be slower than in younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Those subjects who metabolize glucocorticoids more slowly may be more likely to develop side effects (",
"    <a class=\"graphic graphic_figure graphicRef59504 \" href=\"UTD.htm?5/27/5566\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/11\">",
"     11",
"    </a>",
"    ], but whether there are distinct subgroups is uncertain. In addition to genetic variability, other drugs can influence the plasma clearance rate of steroids. CBG binding is not a major determinant of plasma half-lives for synthetic steroids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Activation and inactivation in target cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 11-beta-hydroxysteroid dehydrogenase type 1 isoenzyme, which converts inactive cortisone to cortisol, is expressed in many glucocorticoid target tissues. The type 2 isoenzyme, which converts cortisol to cortisone, is found mainly in mineralocorticoid target tissues (kidney, colon, salivary glands) and in the placenta, in which it protects the cell from cortisol activation of the corticosteroid type 1 (mineralocorticoid) receptor. Glucocorticoids that are fluorinated at the 6-alpha or 9-alpha position (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    ) or methylated at the 6-alpha position (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ), or methyloxazoline at position 16,17 (deflazacort), are protected from oxidation inactivation by the type 2 isoenzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/12\">",
"     12",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is more effectively oxidized by 11 beta-hydroxysteroid dehydrogenase type 2 than is cortisol, which may explain why prednisone has less salt-retaining activity than cortisol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Metabolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exogenous glucocorticoids are subject to the same reduction, oxidation, hydroxylation, and conjugation reactions as endogenous steroids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9240?source=see_link\">",
"     \"Metabolism of adrenal steroids\"",
"    </a>",
"    .) Certain drugs (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/40/29321?source=see_link\">",
"     phenobarbital",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/48/35594?source=see_link\">",
"     phenytoin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/58/16293?source=see_link\">",
"     mitotane",
"    </a>",
"    ) increase the metabolism of synthetic and natural glucocorticoids similarly, particularly by increasing hepatic 6-beta-hydroxylase activity of CYP3A4 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/13-17\">",
"     13-17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9240?source=see_link\">",
"     \"Metabolism of adrenal steroids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31703?source=see_link&amp;anchor=H17#H17\">",
"     \"Determinants of glucocorticoid dosing\", section on 'Drug interactions'",
"    </a>",
"    .) Administration of inhibitors of CYP3A4 shows that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    concentrations increase, indicating that these agents are metabolized by this enzyme. However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) is not affected [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Assays of biologic activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potencies of synthetic glucocorticoids have been assessed in bioassays that do not account for their variable absorption and metabolism. Classic bioassays test the ability of the glucocorticoid to lower the circulating eosinophil count in humans, and to stimulate hepatic glycogen deposition and inhibit inflammation after subcutaneous oil injection in rats. The last two assays presumably measure directly the \"glucocorticoid\" and \"antiinflammatory\" potency of the test compound, respectively.",
"   </p>",
"   <p>",
"    The results of several studies from a number of sources are summarized in the table, which also shows the ability of the glucocorticoid to inhibit sodium excretion in adrenalectomized rats, an index of mineralocorticoid activity, and the ability of the agents to bind to the cytosolic glucocorticoid receptor (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/19-23\">",
"     19-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Like cortisone, which must be converted to cortisol by hepatic 11&szlig;-hydroxysteroid dehydrogenase,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    must be converted to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    to exert any glucocorticoid action [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     CRITERIA FOR INITIATING THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Medical emergencies",
"    </span>",
"    &nbsp;&mdash;&nbsp;High doses of glucocorticoids can be administered for a few days with little risk. It may, therefore, be warranted to use them in emergency situations in which therapeutic benefit has not been demonstrated but might be anticipated, but they should not be given for more than a few days for these conditions. Their use must never replace or delay more specific primary therapies, such as antibiotics in septic shock or epinephrine and antihistamines in anaphylaxis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Chronic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In less urgent circumstances, more careful consideration must be given to the evidence for glucocorticoid efficacy; the particular preparation to be used; its dose, frequency, and route of administration; and the disease indexes to be monitored to assess therapeutic efficacy. Glucocorticoids cannot be given chronically without the risk of adverse effects. As an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    doses as low as 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    can lead to bone loss. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The criteria one should apply before initiating chronic glucocorticoid therapy are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef51920 \" href=\"UTD.htm?6/41/6811\">",
"     table 2",
"    </a>",
"    ). Use of objective criteria of response deserves special emphasis. In addition to the potential placebo effects of any therapy, glucocorticoids tend to make almost everyone feel better acutely. Therefore, subjective improvement is not a useful criterion of response. Rather, air flow in asthma, serum aminotransferase concentrations in autoimmune hepatitis, and similar quantifiable end points in other diseases should be used to determine if glucocorticoids are achieving their desired effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ROUTE OF ADMINISTRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dose and route of administration depend on the disorder being treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Parenteral therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parenteral administration of high doses may be warranted in emergencies, such as septic shock and severe acute asthma. Intravenous (\"pulse\") bolus doses of 1 to 2 g of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    have been used to treat transplant rejection and some autoimmune diseases such as severe lupus nephritis and crescentic glomerulonephritis.",
"   </p>",
"   <p>",
"    The mechanism of action of such massive doses remains to be established. Glucocorticoids appear to act in part by inducing the synthesis of IkBa, a protein that traps and thereby inactivates nuclear factor kappa B [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The latter protein is an activator of cytokine genes and a mediator of the proinflammatory action of tumor necrosis factor. Pulse glucocorticoid administration may impair cytokine generation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/27\">",
"     27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another possible mechanism is a direct effect upon cell membranes. In extremely high doses, glucocorticoids dissolve in cell membranes, thereby altering their physicochemical properties and the activities of membrane-associated proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/28\">",
"     28",
"    </a>",
"    ], which may explain why only high doses are effective in treating acute exacerbations of immunologically-mediated diseases.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Oral administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Oral preparations are usually used for chronic therapy. They are absorbed almost quantitatively within about 30 minutes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Nonsystemic administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;When possible, nonsystemic glucocorticoid therapy should be used in an attempt to deliver higher local concentrations while minimizing systemic exposure. Intraarticular injection for joint inflammation, inhalation therapy for asthma, and topical application for inflammatory skin disorders are examples.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injected glucocorticoids vary considerably in the rate of their absorption.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       Hydrocortisone",
"      </a>",
"      salts are absorbed from an intramuscular injection site within minutes, and less soluble esters are absorbed within one hour.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39174?source=see_link\">",
"       Cortisone acetate",
"      </a>",
"      is more slowly absorbed, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"       triamcinolone",
"      </a>",
"      salts and esters are absorbed even more slowly. Absorption from intraarticular sites can be highly variable. As an example, a single large intrabursal injection of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      can cause persistent Cushing's syndrome.",
"     </li>",
"     <li>",
"      All topical and inhaled glucocorticoids are absorbed to some extent and, therefore, have the potential for causing hypothalamic-pituitary-adrenal axis suppression and Cushing's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"       \"Major side effects of inhaled glucocorticoids\"",
"      </a>",
"      .) In particular, inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      propionate (Flonase&copy;, Flovent&copy;) appears to have greater systemic absorption and a greater association with adrenal suppression [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/32\">",
"       32",
"      </a>",
"      ]. Topical therapy can also cause skin atrophy, ecchymoses, purple striae, dermatoses, and cataracts [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Absorption of topically administered glucocorticoids varies depending on:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The area of the body on which it is applied (eg, intertriginous areas &gt; forehead &gt; scalp &gt; face &gt; forearm) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/33\">",
"       33",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Whether the vehicle contains urea,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/22/33123?source=see_link\">",
"       dimethylsulfoxide",
"      </a>",
"      , or other agents (eg, salicylic acid) that increase absorption",
"     </li>",
"     <li>",
"      Whether the area is covered with an occlusive dressing, which may increase absorption as much as 10-fold [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/34\">",
"       34",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The skin integrity; glucocorticoids are absorbed through areas of inflammation and desquamation better than normal skin",
"     </li>",
"     <li>",
"      The patient's age; infants and young children, whose stratum corneum is much thinner than that of adults, absorb topical steroids more readily [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/35\">",
"       35",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DOSE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Apart from the treatment of adrenal insufficiency, glucocorticoid therapy usually involves giving supraphysiologic doses. In some diseases, such as mild rheumatoid arthritis, chronic control may be achieved with doses equivalent to or even less than normal daily adrenal production [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The glucocorticoid most often used is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , which has a relatively short half-life in plasma; the rate of clearance may determine the risk of side effects (",
"    <a class=\"graphic graphic_figure graphicRef59504 \" href=\"UTD.htm?5/27/5566\">",
"     figure 3",
"    </a>",
"    ). This phenomenon has not been studied carefully, but presumably prednisone, usually given as a single dose early in the morning, does not suppress the circadian peak in cortisol secretion the next morning. Thus, the patient is exposed to the sum of the exogenous prednisone plus his own normal or near-normal cortisol production. More recently, a formulation of prednisone with delayed release four hours after ingestion was shown to be superior to the conventional formulation in reduction of morning stiffness, without further suppression of the hypothalamic-pituitary-adrenal axis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/38\">",
"     38",
"    </a>",
"    ]. The mechanism of this so-called &ldquo;chronotherapy&rdquo; is postulated to be suppression of the nocturnal rise of pro-inflammatory cytokines.",
"   </p>",
"   <p>",
"    The potential advantage of such a regimen, when chronic low-dose therapy is required, is maintenance of normal hypothalamic-pituitary-adrenal function. However, toxicity such as bone loss can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/37\">",
"     37",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    doses as low as 0.075",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    doses as low as 0.3",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    per day can inhibit linear growth in children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/39\">",
"     39",
"    </a>",
"    ]. The dose equivalents of other oral glucocorticoids are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef64138 \" href=\"UTD.htm?41/61/42972\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Alternate-day administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alternate-day regimens were devised in an attempt to alleviate the undesirable side effects of chronic high-dose daily glucocorticoid therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. Approximately twice the usual daily dose is given on alternate days, the rationale being that the patient is not exposed to high glucocorticoid concentrations every day and therefore has less chance of developing Cushing's syndrome or pituitary suppression. Unfortunately, alternate-day therapy is unsuccessful in virtually all adult patients who require high doses of glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     COMPLICATIONS OF CHRONIC USE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of glucocorticoid therapy, as with any therapy, is to obtain maximum benefit with minimum adverse side effects. Potent synthetic glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/38/39520?source=see_link\">",
"     triamcinolone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    ) have little mineralocorticoid, androgenic, or estrogenic activity. As a result, the major systemic side effects are those of suppression of hypothalamic-pituitary-adrenal function and Cushing's syndrome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     HPA axis suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both endogenous and exogenous glucocorticoids exert negative feedback control on the hypothalamic-pituitary-adrenal axis by suppressing hypothalamic corticotropin-releasing hormone (CRH) production and pituitary corticotropin (ACTH) secretion. This leads to adrenal atrophy and loss of cortisol secretory capability. The first well-documented case of adrenal insufficiency after exogenous glucocorticoid withdrawal was reported in 1961 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/42\">",
"     42",
"    </a>",
"    ], less than 10 years after glucocorticoids became widely available for therapeutic use.",
"   </p>",
"   <p>",
"    The time required to achieve suppression depends upon the dose and varies among patients, probably because of differences in their rates of glucocorticoid metabolism (",
"    <a class=\"graphic graphic_figure graphicRef59504 \" href=\"UTD.htm?5/27/5566\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Not suppressed",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following patients can be considered not to have suppression of their hypothalamic-pituitary-adrenal axis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Any patient who has received any non-parenteral dose of glucocorticoid for less than three weeks",
"     </li>",
"     <li>",
"      Patients treated with alternate-day glucocorticoid therapy at physiologic doses [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/40,41,43\">",
"       40,41,43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Suppressed",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast, patients who should be assumed to have functional suppression of hypothalamic-pituitary-adrenal function include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anyone who has received more than 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      a day for more than three weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/44\">",
"       44",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Any patient who has clinical Cushing's syndrome",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Such patients do not need testing to evaluate their hypothalamic-pituitary-adrenal function, but should be treated like any patient with secondary adrenal insufficiency, including having them wear a medical alert bracelet or necklace, carry an emergency medical information card and, arguably, carry a preloaded 1 mL syringe containing 4 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    phosphate to inject in emergencies. In addition, glucocorticoid therapy should be tapered gradually to permit recovery of hypothalamic-pituitary-adrenal function. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Uncertain suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;This intermediate category includes patients who may have hypothalamic-pituitary-adrenal suppression. Patients taking supraphysiologic doses of glucocorticoid for three to six weeks may or may not have clinically important suppression of hypothalamic-pituitary-adrenal function [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/45\">",
"     45",
"    </a>",
"    ]. These patients should undergo a cosyntropin stimulation test to evaluate the responsiveness of the adrenal if therapy is going to be discontinued abruptly. If a known acute stress such as surgery is anticipated, one can give stress doses of glucocorticoids or, if time permits, test for the responsiveness of the adrenal gland. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=see_link\">",
"     \"Evaluation of the response to ACTH in adrenal insufficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Also included in the uncertain suppression group is any patient who has taken less than 10 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or its equivalent per day, providing that it is not taken as a single bedtime dose [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/46\">",
"     46",
"    </a>",
"    ] for more than a few weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Although a few such patients may have inadequate responses to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/12/15556?source=see_link\">",
"     metyrapone",
"    </a>",
"    , low-dose ACTH, or hypoglycemia for brief intervals after cessation of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], the incidence of clinical adrenal insufficiency is exceedingly low [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/2,9,51\">",
"     2,9,51",
"    </a>",
"    ]. Nevertheless, some clinicians recommend stress doses of glucocorticoid in such patients during major stresses, such as surgery or trauma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Iatrogenic Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with hypothalamic-pituitary-adrenal axis suppression, development of Cushing's syndrome depends upon the dose, timing, and duration of glucocorticoid administration and varies among patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Signs of Cushing's syndrome can occur within a month after beginning high-dose glucocorticoid therapy. Certain features are more common in patients with iatrogenic than in those with endogenous Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/2,52\">",
"     2,52",
"    </a>",
"    ]. They include causing or worsening glaucoma, formation of posterior subcapsular cataracts, benign intracranial hypertension, osteonecrosis of the femoral and humeral heads, pancreatitis, and panniculitis. They appear to reflect the severity and the chronicity of the glucocorticoid excess. Osteoporosis is one of the most common and serious complications, while hypertension, hirsutism, acne, menstrual disturbances, and erectile dysfunction are rare. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other complications that can occur include loss of muscle mass, weakness, worsening of diabetes mellitus, increased susceptibility to infection, poor wound healing, weight gain, activation of latent granulomatous infections, arrest of linear growth in children, and psychiatric disturbances.",
"   </p>",
"   <p>",
"    In children with acute lymphoblastic anemia treated for only five days with equivalent doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , appetite increased and caloric consumption increased 10 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23208/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Iatrogenic Cushing&rsquo;s syndrome and withdrawal from glucocorticoid therapy are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=see_link&amp;anchor=H10#H10\">",
"     \"Causes of secondary and tertiary adrenal insufficiency in adults\", section on 'Chronic high-dose glucocorticoid therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=see_link&amp;anchor=H10#H10\">",
"     \"Glucocorticoid withdrawal\", section on 'Estimation of HPA suppression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     MINIMIZING GLUCOCORTICOID SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to minimizing the exposure to glucocorticoids, certain measures may ameliorate their undesirable side effects.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Exercise programs may reduce the risk of myopathy and osteoporosis.",
"     </li>",
"     <li>",
"      Exercise, calcium, vitamin D, bisphosphonates and, in postmenopausal women, estrogen therapy, may minimize glucocorticoid-induced lumbar vertebral bone mineral loss, but none of these treatments appear to prevent loss from the femoral neck or distal radius. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=see_link\">",
"       \"Prevention and treatment of glucocorticoid-induced osteoporosis\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=see_link\">",
"       \"Patient information: Steroid medicines (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that influence both the therapeutic and adverse effects of glucocorticoids include the biologic potency, pharmacokinetic properties of the glucocorticoid, daily dose, timing of doses during the day, individual differences in steroid metabolism, and the duration of treatment.",
"   </p>",
"   <p>",
"    Acutely, high doses of glucocorticoids can be given parenterally for a few days without causing adverse effects.",
"   </p>",
"   <p>",
"    For chronic therapy, glucocorticoids should be chosen only if there is good evidence that they are effective and optimal treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment efficacy should be monitored with quantitative measurements rather than subjective well-being.",
"     </li>",
"     <li>",
"      The smallest effective dose for the least amount of time is the goal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    When possible, nonsystemic glucocorticoid therapy should be used to minimize adverse effects of systemic exposure.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All nonsystemic steroids have some systemic absorption.",
"     </li>",
"     <li>",
"      Topical steroid absorption depends on the area of the body on which it is applied, the type of the vehicle, use of an occlusive dressing, skin integrity, and the patient's age.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Complications of glucocorticoid therapy include suppression of hypothalamic-pituitary-adrenal function and Cushing's syndrome.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The time required to develop these complications depends upon the dose and duration of therapy and varies among patients.",
"     </li>",
"     <li>",
"      Suppression is unlikely in patients receiving non-parenteral steroids for less than three weeks or alternate-day glucocorticoids at physiologic doses.",
"     </li>",
"     <li>",
"      Suppression can be assumed in patients receiving more than 20 mg of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      a day for more than three weeks and any patient who has clinical Cushing's syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Certain measures may ameliorate undesirable side effects, including exercise programs to reduce the risk of myopathy and osteoporosis, and calcium, vitamin D, bisphosphonates and, in postmenopausal women, estrogen therapy to minimize lumbar vertebral bone mineral loss.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dluhy RG, Newmark SR, Lauler DP, Thorn GW. Pharmacology and chemistry of adrenal glucocorticoids. In: Steroid therapy, Azarnoff DL.  (Ed), WB Saunders, Philadelphia 1975. p.1.",
"    </li>",
"    <li>",
"     Christy NP. Principles of systemic corticosteroid therapy in nonendocrine disease. In: Current Therapy in Endocrinology and Metabolism, 3rd Ed, Bardin CW (Ed), BC Decker, New York 1988. p.104.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/3\">",
"      HERZOG HL, NOBILE A, TOLKSDORF S, et al. New antiarthritic steroids. Science 1955; 121:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/4\">",
"      STAFFORD RO, BARNES LE, BOWMAN BJ, MEINZINGER MM. Glucocorticoid and mineralocorticoids activities of delta1-fluorohydrocortisone. Proc Soc Exp Biol Med 1955; 89:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/5\">",
"      Migeon, CJ, Lawrence, B, Bertrand, J, Holman, GH. In vivo distribution of some 17-hydroxycorticoids between the plasma and red blood cells of man. J Clin Endocrinol Metab 1959; 19:1411.",
"     </a>",
"    </li>",
"    <li>",
"     Ballard PL. Delivery and transport of glucocorticoids to target cells. In: Glucocorticoid Hormone Action, Baxter JD, Rousseau GG (Eds), Springer-Verlag, Berlin 1979. p.25.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/7\">",
"      NUGENT CA, EIK-NES K, SAMUELS LT, TYLER FH. Changes in plasma levels of 17-hydroxycorticosteroids during the intravenous administration of adrenocorticotropin (ACTH). IV. Response to prolonged infusions of small amounts of ACTH. J Clin Endocrinol Metab 1959; 19:334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/8\">",
"      PETERSON RE. Metabolism of adrenocorticosteroids in man. Ann N Y Acad Sci 1959; 82:846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/9\">",
"      Axelrod L. Glucocorticoid therapy. Medicine (Baltimore) 1976; 55:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/10\">",
"      Tornatore KM, Logue G, Venuto RC, Davis PJ. Cortisol pharmacodynamics after methylprednisolone administration in young and elderly males. J Clin Pharmacol 1997; 37:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/11\">",
"      Kozower M, Veatch L, Kaplan MM. Decreased clearance of prednisolone, a factor in the development of corticosteroid side effects. J Clin Endocrinol Metab 1974; 38:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/12\">",
"      Diederich S, Eigendorff E, Burkhardt P, et al. 11beta-hydroxysteroid dehydrogenase types 1 and 2: an important pharmacokinetic determinant for the activity of synthetic mineralo- and glucocorticoids. J Clin Endocrinol Metab 2002; 87:5695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/13\">",
"      BURSTEIN S, KLAIBER EL. PHENOBARBITAL-INDUCED INCREASE IN 6-BETA-HYDROXYCORTISOL EXCRETION: CLUE TO ITS SIGNIFICANCE IN HUMAN URINE. J Clin Endocrinol Metab 1965; 25:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/14\">",
"      WERK EE Jr, MACGEE J, SHOLITON LJ. EFFECT OF DIPHENYLHYDANTOIN ON CORTISOL METABOLISM IN MAN. J Clin Invest 1964; 43:1824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/15\">",
"      Yamada S, Iwai K. Letter: Induction of hepatic cortisol-6-hydroxylase by rifampicin. Lancet 1976; 2:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/16\">",
"      BLEDSOE T, ISLAND DP, NEY RL, LIDDLE GW. AN EFFECT OF O,P'-DDD ON THE EXTRA-ADRENAL METABOLISM OF CORTISOL IN MAN. J Clin Endocrinol Metab 1964; 24:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/17\">",
"      Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999; 39:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/18\">",
"      Lebrun-Vignes B, Archer VC, Diquet B, et al. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects. Br J Clin Pharmacol 2001; 51:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/19\">",
"      Meikle AW, Tyler FH. Potency and duration of action of glucocorticoids. Effects of hydrocortisone, prednisone and dexamethasone on human pituitary-adrenal function. Am J Med 1977; 63:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/20\">",
"      Liddle, GW. Studies of structure-function relationships of steroids. II. The 6a-methylcorticosteroids. Metabolism 1958; 7:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/21\">",
"      DULIN WE. Anti-inflammatory activity of delta1-9alpha-fluorohydrocortisone acetate. Proc Soc Exp Biol Med 1955; 90:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/22\">",
"      SOFFER LJ, ORR RH. Symposium: newer hydrocortisone analogs. Metabolism 1958; 7:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/23\">",
"      DULIN WE, BARNES LE, GLENN EM, et al. Biologic activities of some C21 steroids and some 6 alpha-methyl C21 steroids. Metabolism 1958; 7:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/24\">",
"      Meikle AW, Weed JA, Tyler FH. Kinetics and interconversion of prednisolone and prednisone studied with new radioimmunogassays. J Clin Endocrinol Metab 1975; 41:717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/25\">",
"      Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS Jr. Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science 1995; 270:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/26\">",
"      Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science 1995; 270:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/27\">",
"      Yokoyama H, Takabatake T, Takaeda M, et al. Up-regulated MHC-class II expression and gamma-IFN and soluble IL-2R in lupus nephritis. Kidney Int 1992; 42:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/28\">",
"      Buttgereit F, Wehling M, Burmester GR. A new hypothesis of modular glucocorticoid actions: steroid treatment of rheumatic diseases revisited. Arthritis Rheum 1998; 41:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/29\">",
"      Kehlet H, Binder C, Blichert-Toft M. Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation. Clin Endocrinol (Oxf) 1976; 5:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/30\">",
"      Walsh P, Aeling JL, Huff L, Weston WL. Hypothalamus-pituitary-adrenal axis suppression by superpotent topical steroids. J Am Acad Dermatol 1993; 29:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/31\">",
"      Keipert JA, Kelly R. Temporary Cushing's syndrome from percutaneous absorption of betamethasone 17-valerate. Med J Aust 1971; 1:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/32\">",
"      Ng PC, Fok TF, Wong GW, et al. Pituitary-adrenal suppression in preterm, very low birth weight infants after inhaled fluticasone propionate treatment. J Clin Endocrinol Metab 1998; 83:2390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/33\">",
"      Fisher DA. Adverse effects of topical corticosteroid use. West J Med 1995; 162:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/34\">",
"      FELDMANN RJ, MAIBACH HI. PENETRATION OF 14C HYDROCORTISONE THROUGH NORMAL SKIN: THE EFFECT OF STRIPPING AND OCCLUSION. Arch Dermatol 1965; 91:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/35\">",
"      Feiwel M, James VH, Barnett ES. Effect of potent topical steroids on plasma-cortisol levels of infants and children with eczema. Lancet 1969; 1:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/36\">",
"      Garber, EK, Fan, PT, Bluestone, R. Realistic guidelines in corticosteroid therapy of rheumatic disease. Semin Arthritis Rheum 1981; 11:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/37\">",
"      Laan RF, van Riel PL, van de Putte LB, et al. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. A randomized, controlled study. Ann Intern Med 1993; 119:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/38\">",
"      Spies CM, Cutolo M, Straub RH, et al. Prednisone chronotherapy. Clin Exp Rheumatol 2011; 29:S42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/39\">",
"      Allen DB, Julius JR, Breen TJ, Attie KM. Treatment of glucocorticoid-induced growth suppression with growth hormone. National Cooperative Growth Study. J Clin Endocrinol Metab 1998; 83:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/40\">",
"      HARTER JG, REDDY WJ, THORN GW. STUDIES ON AN INTERMITTENT CORTICOSTEROID DOSAGE REGIMEN. N Engl J Med 1963; 269:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/41\">",
"      Fauci AS. Alternate-day corticosteroid therapy. Am J Med 1978; 64:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/42\">",
"      SAMPSON PA, BROOKE BN, WINSTONE NE. Biochemical confirmation of collapse due to adrenal failure. Lancet 1961; 1:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/43\">",
"      Ackerman GL, Nolsn CM. Adrenocortical responsiveness after alternate-day corticosteroid therapy. N Engl J Med 1968; 278:405.",
"     </a>",
"    </li>",
"    <li>",
"     Christy NP. Corticosteroid withdrawal. In: Current Therapy in Endocrinology and Metabolism, 3rd Ed, Bardin CW (Ed), BC Decker, New York 1988. p.113.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/45\">",
"      Kuperman H, Damiani D, Chrousos GP, et al. Evaluation of the hypothalamic-pituitary-adrenal axis in children with leukemia before and after 6 weeks of high-dose glucocorticoid therapy. J Clin Endocrinol Metab 2001; 86:2993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/46\">",
"      NICHOLS T, NUGENT CA, TYLER FH. DIURNAL VARIATION IN SUPPRESSION OF ADRENAL FUNCTION BY GLUCOCORTICOIDS. J Clin Endocrinol Metab 1965; 25:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/47\">",
"      Myles AB, Bacon PA, Daly JR. Single daily dose corticosteroid treatment. Effect on adrenal function and therapeutic efficacy in various diseases. Ann Rheum Dis 1971; 30:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/48\">",
"      DANOWSKI TS, BONESSI JV, SABEH G, et al. PROBABILITIES OF PITUITARY-ADRENAL RESPONSIVENESS AFTER STEROID THERAPY. Ann Intern Med 1964; 61:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/49\">",
"      Streck WF, Lockwood DH. Pituitary adrenal recovery following short-term suppression with corticosteroids. Am J Med 1979; 66:910.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/50\">",
"      Spiegel RJ, Vigersky RA, Oliff AI, et al. Adrenal suppression after short-term corticosteroid therapy. Lancet 1979; 1:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/51\">",
"      Livanou T, Ferriman D, James VH. Recovery of hypothalamo-pituitary-adrenal function after corticosteroid therapy. Lancet 1967; 2:856.",
"     </a>",
"    </li>",
"    <li>",
"     Christy NP. Iatrogenic Cushing's syndrome. In: The Human Adrenal Cortex, Christy NP (Ed), Harper and Row, New York 1979. p.395.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23208/abstract/53\">",
"      Reilly JJ, Brougham M, Montgomery C, et al. Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab 2001; 86:3742.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 124 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-2D9DC08A38-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23208=[""].join("\n");
var outline_f22_42_23208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      STRUCTURES OF COMMON SYNTHETIC STEROIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Plasma disappearance half-life",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Activation and inactivation in target cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Metabolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Assays of biologic activity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CRITERIA FOR INITIATING THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Medical emergencies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ROUTE OF ADMINISTRATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Parenteral therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Oral administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Nonsystemic administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DOSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Alternate-day administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      COMPLICATIONS OF CHRONIC USE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      HPA axis suppression",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Not suppressed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Suppressed",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Uncertain suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Iatrogenic Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      MINIMIZING GLUCOCORTICOID SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/124\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/124|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/19/11582\" title=\"figure 1\">",
"      Glucocorticoid structure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/44/40655\" title=\"figure 2\">",
"      Steroid modifications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?5/27/5566\" title=\"figure 3\">",
"      Prednisone metabolism toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/124|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?41/61/42972\" title=\"table 1\">",
"      Relative potency glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?6/41/6811\" title=\"table 2\">",
"      Guidelines pharmacologic glucocorticoids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=related_link\">",
"      Causes of secondary and tertiary adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/61/31703?source=related_link\">",
"      Determinants of glucocorticoid dosing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/20/24905?source=related_link\">",
"      Evaluation of the response to ACTH in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/1/9240?source=related_link\">",
"      Metabolism of adrenal steroids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/57/37778?source=related_link\">",
"      Patient information: Steroid medicines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/36/17994?source=related_link\">",
"      Prevention and treatment of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_42_23209="Slipped capital femoral epiphysis (SCFE)";
var content_f22_42_23209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Slipped capital femoral epiphysis (SCFE)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23209/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23209/contributors\">",
"     Andrew J Kienstra, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23209/contributors\">",
"     Charles G Macias, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23209/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23209/contributors\">",
"     William Phillips, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23209/contributors\">",
"     Jonathan I Singer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23209/contributors\">",
"     James F Wiley, II, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/42/23209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 23, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Slipped capital femoral epiphysis (SCFE), also called slipped upper femoral epiphysis (SUFE) and physiolysis of the hip, is characterized by a displacement of the capital femoral epiphysis from the femoral neck through the physeal plate. It is one of the most common hip disorders of adolescence. Approximately 15 percent of patients present with isolated thigh or knee pain, so physicians must have a high degree of suspicion to prevent delay in diagnosis, which can worsen prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCFE occurs in approximately 1 per 1000 to 1 per 10,000 children and young adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. The epidemiology of SCFE was defined in a multinational study of more than 1600 children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/4\">",
"     4",
"    </a>",
"    ]. The typical patient is an obese child in early adolescence who, if female, has not yet reached menarche, and if male, has not yet reached the fourth Tanner stage. The mean age of presentation is 12 years in girls and 13.5 years in boys, near the time of peak linear growth. The male-to-female ratio is approximately 1.5:1. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SCFE is bilateral in 20 to 40 percent of cases at presentation. In children who present with unilateral disease, the contralateral hip slips in an additional 30 to 60 percent, and in up to 100 percent of patients with underlying endocrine disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. In unilateral slips, the left hip is affected somewhat more often than the right, for unknown reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Obesity is a significant risk factor in the development of idiopathic SCFE. In the multinational study described above, more than 60 percent of patients measured greater than or equal to the 90",
"    <sup>",
"     th",
"    </sup>",
"    percentile weight for age and sex [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, the increased prevalence of adolescent obesity has been associated with a marked increase in the frequency of SCFE in selected regional and national populations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=see_link\">",
"     \"Comorbidities and complications of obesity in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Additional risk factors include renal failure [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/10\">",
"     10",
"    </a>",
"    ], history of radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/11\">",
"     11",
"    </a>",
"    ], endocrine abnormalities (particularly hypothyroidism and growth hormone deficiency) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/12-14\">",
"     12-14",
"    </a>",
"    ], and various genetic disorders (eg, Down and Rubenstein-Taybi syndromes) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. When SCFE occurs in association with one of these additional risk factors, it is called atypical SCFE [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/17\">",
"     17",
"    </a>",
"    ]. Atypical SCFE is more common among children who are younger than 10 years, older than 16 years, whose weight is &lt;50",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age, or whose height is &lt;10",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/12,17,18\">",
"     12,17,18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term SCFE is a misnomer. It is actually the portion of the proximal femur distal to the physis (growth plate) that is displaced anterolaterally and superiorly [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/19\">",
"     19",
"    </a>",
"    ]. This displacement gives the appearance of posterior and inferior displacement of the epiphysis, which in fact remains in normal position in the acetabulum.",
"   </p>",
"   <p>",
"    In rare cases, usually in tall, thin adolescents, the femoral neck is displaced downward and anteriorly in relation to the femoral head. In contrast to the typical varus angulation, the femoral head-neck shaft angle in these cases is widened (valgus angulation or coxa valga) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    SCFE occurs when shearing forces applied to the femoral head exceed the strength of the capital femoral physis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/21\">",
"     21",
"    </a>",
"    ]. The factors that weaken the physeal plate are not fully clarified, but are thought to include [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Normal periosteal thinning and widening of the physis, which occurs during adolescence and other periods of rapid growth acceleration [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/23-25\">",
"       23-25",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Trauma (particularly in acute and acute-on-chronic slips)",
"     </li>",
"     <li>",
"      Obesity, which increases mechanical strain on the physis",
"     </li>",
"     <li>",
"      Inflammatory changes",
"     </li>",
"     <li>",
"      Genetic predisposition [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/26-29\">",
"       26-29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Endocrine and metabolic disorders (eg, hypothyroidism and growth hormone deficiency, which can cause abnormal growth and mineralization of cartilage) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The two most common features of the presentation of SCFE are pain and altered gait [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/21\">",
"     21",
"    </a>",
"    ]. The classic presentation is that of an obese adolescent with a complaint of nonradiating, dull, aching pain in the hip, groin, thigh, or knee, and no history of preceding trauma. The pain is increased by physical activity and may be chronic or intermittent. SCFE may be classified according to its pattern of presentation, stability, or severity. These classifications are discussed below. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=see_link\">",
"     \"Approach to the child with a limp\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Presentation patterns",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCFE is traditionally classified into four patterns of presentation on the basis of intensity and duration of symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/32\">",
"     32",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Preslip",
"     </li>",
"     <li>",
"      Acute",
"     </li>",
"     <li>",
"      Acute-on-chronic",
"     </li>",
"     <li>",
"      Chronic",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Preslip",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with preslip SCFE have pain but no discernible displacement of the epiphysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/21\">",
"     21",
"    </a>",
"    ]. Radiographs demonstrate widening of the proximal femoral physis compared with the opposite asymptomatic hip.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Acute",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with acute SCFE have symptoms of less than three weeks' duration. Joint effusion is present, but there is no metaphyseal remodeling [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/33\">",
"     33",
"    </a>",
"    ]. Acute presentation occurs in 10 to 15 percent of patients with SCFE, and often is associated with trauma [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/4,34,35\">",
"     4,34,35",
"    </a>",
"    ]. Acute traumatic slips may occur following major trauma (eg, fall from height or motor vehicle accident).",
"   </p>",
"   <p>",
"    Symptoms include onset of severe pain, external rotational deformity, limited range of motion of the hip, shortening, and commonly, inability to bear weight [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/35\">",
"     35",
"    </a>",
"    ]. Active motion of the hip is severely limited by muscle spasm, and the patient complains of intense pain with any attempt at passive motion.",
"   </p>",
"   <p>",
"    Patients with acute symptoms of SCFE are at risk of further displacement of the epiphysis. To avoid this and for pain relief, patients with an acute slip should immediately be placed on crutches, in a wheelchair or on a stretcher and remain non-weightbearing until they have received definitive treatment. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Stability'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H18\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Acute-on-chronic",
"    </span>",
"    &nbsp;&mdash;&nbsp;The acute-on-chronic presentation occurs when a patient with a history of symptoms and signs of chronic SCFE (eg, limp and or pain of at least three weeks duration) presents with an acute increase in pain and loss of motion of the affected hip [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/32\">",
"     32",
"    </a>",
"    ]. Joint effusion and metaphyseal remodeling are present [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Chronic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic SCFE is the most common pattern of presentation. It is characterized by vague, intermittent symptoms over a protracted period, usually considered to be longer than three weeks. Metaphyseal remodeling is present, but there is no effusion [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The classic presentation is that of an obese adolescent with a complaint of nonradiating, dull, aching pain in the hip, groin, thigh, or knee and no history of preceding trauma. Approximately 15 percent of patients present with isolated thigh or knee pain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/37\">",
"     37",
"    </a>",
"    ]. SCFE is more likely to be missed at the initial visit if hip pain is absent or thigh pain is present [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/1,37,38\">",
"     1,37,38",
"    </a>",
"    ], so physicians must have a high degree of suspicion to prevent delay in diagnosis, which can worsen prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The pain may be chronic or intermittent; it is increased by physical activity and relieved with rest (although this may take up to an hour to achieve) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/39\">",
"     39",
"    </a>",
"    ]. Patients usually have already limited their participation in strenuous or sporting activities because of discomfort.",
"   </p>",
"   <p>",
"    Patients with idiopathic SCFE usually are obese. However, they may be tall and thin, indicating a rapid growth spurt [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20\">",
"     20",
"    </a>",
"    ]. The patient usually has an altered gait. The foot on the affected side is usually turned out more than its mate. If the SCFE is unilateral, the gait may be antalgic: the patient takes a short step on the affected side to minimize weightbearing, which is painful, during the stance phase (",
"    <a class=\"graphic graphic_figure graphicRef53103 \" href=\"UTD.htm?6/5/6224\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20\">",
"     20",
"    </a>",
"    ]. In moderate or severe unilateral slips, there may be a Trendelenburg gait: a shift of the torso over the affected hip (",
"    <a class=\"graphic graphic_picture graphicRef74735 \" href=\"UTD.htm?2/50/2853\">",
"     picture 1",
"    </a>",
"    ). If the SCFE is bilateral, the gait is usually waddling. The affected leg is usually held in an externally rotated position and may be shorter than the unaffected leg. Disuse atrophy of the upper thigh and gluteal muscle may be present in moderate or severe slips, but may be difficult to appreciate in an obese patient.",
"   </p>",
"   <p>",
"    The anterior hip may be tender to palpation. In contrast, despite a complaint of pain in the knee area, localized tenderness to palpation of this area is not present. The remainder of the knee examination is normal as well.",
"   </p>",
"   <p>",
"    Range of motion of the hip is decreased with internal rotation, abduction, and flexion, but may be painful in all directions. The degree of restriction of range of motion depends upon the severity of the slip. Although the range of motion for adduction is usually normal, it should be tested in all patients to detect the rare patient with a valgus slip (ie, coxa valga, discussed below) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20\">",
"     20",
"    </a>",
"    ]. When the hip is passively flexed from an extended position, the thigh of the affected limb abducts and externally rotates [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20,32,36\">",
"     20,32,36",
"    </a>",
"    ]. This finding is highly suggestive of SCFE.",
"   </p>",
"   <p>",
"    Asking the child to stand on the affected leg (the Trendelenburg test) causes a pelvic tilt (the affected side is lower) in children with SCFE if the gluteal muscle has been weakened by chronic SCFE.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coxa valga slips &ndash; Coxa valga is a rare type of slip in which the femoral neck is displaced downward and anteriorly in relation to the femoral head [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20,40\">",
"       20,40",
"      </a>",
"      ]. Similar to patients with varus slips, patients with coxa valga typically complain of anteromedial thigh or knee pain and limited hip flexion on the affected side. However, they have lengthening, rather than shortening, of the affected limb (which leads to a circumduction) and limited range of motion in adduction, rather than abduction. Lateral radiographs are necessary for diagnosis [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;SCFE also has been classified according to biomechanical stability as \"stable\" or \"unstable\" [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/41\">",
"     41",
"    </a>",
"    ]. Stable slips are defined as those in which walking and weightbearing are possible with or without crutches. Unstable slips are those in which the epiphysis is displaced from the metaphysis or the patient is unable to bear weight, even with crutches, regardless of duration of symptoms. Most of these patients present with severe pain similar to a fracture of the hip. Because manipulation may cause further displacement of the epiphysis, patients who have unstable slips should immediately be placed in a wheelchair or on a stretcher and remain non-weightbearing until they have received definitive treatment. Unstable slips are at much higher risk for poor outcomes. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Management'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;A final classification system for SCFE is based upon severity of slippage, which determines prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Long-term outcome'",
"    </a>",
"    below.) The slip is graded as mild, moderate, or severe according to the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A mild slip is one in which the displacement of the epiphysis is less than one-third of the diameter of the femoral neck.",
"     </li>",
"     <li>",
"      A moderate slip is one in which the displacement of the epiphysis is more than one-third but less than one-half of the diameter of the femoral neck.",
"     </li>",
"     <li>",
"      A severe slip is one in which the displacement of the epiphysis is more than one-half of the diameter of the femoral neck.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another method of grading slip severity is according to the epiphyseal-shaft angle of Southwick, which is measured on the frog-leg lateral radiograph (",
"    <a class=\"graphic graphic_figure graphicRef68897 \" href=\"UTD.htm?6/10/6304\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mild slips have &lt;30 degrees of displacement compared to the unaffected side.",
"     </li>",
"     <li>",
"      Moderate slips have between 30 and 50 degrees of displacement compared to the unaffected side.",
"     </li>",
"     <li>",
"      Severe slips have greater than 50 degrees of displacement compared to the unaffected side.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Radiologic evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiographic changes may be minimal before the slip occurs and may be best seen with lateral views. Ultrasonography and magnetic resonance imaging (MRI) also can demonstrate characteristic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/33,39\">",
"     33,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Plain radiographs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most cases of SCFE can be diagnosed with hip radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/43\">",
"     43",
"    </a>",
"    ]. The minimum radiographic examination consists of an anteroposterior (AP) view and lateral projections of both hips. The lateral projections are obtained by the frog-leg or cross-table lateral views; some authors prefer the true lateral radiograph to the frog-leg lateral because of the potential risk of further displacement of the epiphysis with frog-leg views [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Bilateral views or pelvis views are obtained to permit comparison, which may facilitate identification of subtle findings, and because of the high incidence of bilateral disease. For simplicity, it may be better to order an AP radiograph of the pelvis whenever evaluating a patient with a possible slip.",
"   </p>",
"   <p>",
"    Correct interpretation of the radiographs is critical [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/43\">",
"     43",
"    </a>",
"    ]. In as many as 25 percent of cases that are missed [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/45\">",
"     45",
"    </a>",
"    ], radiographs were misinterpreted, or the diagnosis could not be established with the radiographs that were obtained [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/46,47\">",
"     46,47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On the AP view, there may be mild widening, lucency, and irregularity of the physis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/48\">",
"     48",
"    </a>",
"    ]. The most reliable sign of an early slip may be blurring of the junction between the metaphysis and the growth plate (",
"    <a class=\"graphic graphic_figure graphicRef55393 \" href=\"UTD.htm?0/41/656\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/49\">",
"     49",
"    </a>",
"    ]. The height of the epiphysis may be diminished because the femoral head has rotated posteriorly. With posterior slippage of the femoral head, the portion of the head that is located behind the metaphysis may be projected as a semicircular area of increased density on the proximal part of the femoral neck; this is called the \"blanch sign of Steel\" (",
"    <a class=\"graphic graphic_figure graphicRef58172 \" href=\"UTD.htm?36/23/37247\">",
"     figure 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/50\">",
"     50",
"    </a>",
"    ]. In the normal AP view, a line drawn along the superior femoral neck (Klein's line) intersects the lateral portion of the femoral head [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/51\">",
"     51",
"    </a>",
"    ]. In a patient with SCFE, the line passes outside of the epiphysis or just at its superior edge (",
"    <a class=\"graphic graphic_figure graphicRef82443 \" href=\"UTD.htm?31/8/31887\">",
"     figure 5",
"    </a>",
"    ). Also, there may be a smaller portion of the femoral head above the line compared to the contralateral hip (assuming the opposite hip is normal).",
"   </p>",
"   <p>",
"    Lateral projections (either frog-leg views or cross-table lateral views) are necessary to make the diagnosis in approximately 10 to 15 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/49,51\">",
"     49,51",
"    </a>",
"    ]. The posterior displacement and step-off of the epiphysis on the femoral neck are better demonstrated on the lateral view. The cross-table view is recommended in patients who have acute onset of symptoms, since the flexion and abduction of the hip that is necessary for the frog-leg view may displace the physis in these unstable slips [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/21\">",
"     21",
"    </a>",
"    ]. However, in extremely obese patients, it is technically difficult to obtain high-quality cross-table views.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Other studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of SCFE can usually be made with plain radiographs. Additional imaging may be helpful in special circumstances, as described below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Computerized tomography (CT) may be useful in standardizing the assessment of slip severity in chronic slips [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/52\">",
"       52",
"      </a>",
"      ], but has not been shown to be superior to roentgenography [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Compared to plain radiographs and CT, MRI is better able to detect early, radiographically occult but symptomatic preslips [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/54\">",
"       54",
"      </a>",
"      ]. In these patients, MRI demonstrates widening of the physis with surrounding edema, which is essentially diagnostic of the disease [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/55\">",
"       55",
"      </a>",
"      ]. However, radiographs remain the preferred initial diagnostic screening tool for SCFE.",
"     </li>",
"     <li>",
"      MRI and bone scan are useful adjuncts in the evaluation of children with SCFE who are at risk for osteonecrosis. MRI can be used to evaluate femoral head circulation and the extent and distribution of osteonecrosis if osteonecrosis is present. Early in the course of osteonecrosis, bone scan may show decreased uptake in the femoral head, but later bone scans may show increased uptake as the necrotic bone is replaced with new bone. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Osteonecrosis'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultrasonography has little role in the routine evaluation of patients with SCFE [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/32\">",
"     32",
"    </a>",
"    ]. Its use has been described in the diagnosis, staging, and follow-up of SCFE, and is supported by some authors [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/33,56-59\">",
"     33,56-59",
"    </a>",
"    ]. In experienced hands, ultrasonography may confirm the diagnosis of SCFE in a child whose plain radiographs are normal, but MRI is more commonly used in such situations (as described above) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/32,60\">",
"     32,60",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Additional tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;In children who are younger than 10 years, older than 16 years, or weigh less than the 50",
"    <sup>",
"     th",
"    </sup>",
"    percentile for age and gender, atypical causes of SCFE should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/12,17,18,20\">",
"     12,17,18,20",
"    </a>",
"    ]. These include renal failure or endocrine disorders, particularly hypothyroidism. Evaluation for these disorders should be undertaken if clinically indicated. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Age and weight were determined to be predictors of atypical SCFE in multiple logistic regression analysis of demographic data from 285 cases of idiopathic and 148 cases of atypical SCFE [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/17\">",
"     17",
"    </a>",
"    ]. For two patients of equal age, atypical SCFE was 8.4 times more likely among those with weight &lt;50",
"    <sup>",
"     th",
"    </sup>",
"    percentile. For two patients of equal weight, atypical SCFE was 4.2 times more likely among children &lt;10 years or &gt;16 years.",
"   </p>",
"   <p>",
"    Because the findings of hypothyroidism in children may be subtle, some authors recommend screening T4, TSH, and bone age for all patients newly diagnosed with SCFE [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/7\">",
"     7",
"    </a>",
"    ]. Others recommend these tests only for those patients who have height &lt;10",
"    <sup>",
"     th",
"    </sup>",
"    percentile or other evidence of an endocrine disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/12,61\">",
"     12,61",
"    </a>",
"    ]. In one study of 166 patients with SCFE, 13 had an associated endocrinopathy. Ninety percent of SCFE patients and underlying endocrinopathy had height &lt;10",
"    <sup>",
"     th",
"    </sup>",
"    percentile; 99 percent of SCFE patients without endocrinopathy had height &ge;10",
"    <sup>",
"     th",
"    </sup>",
"    percentile (sensitivity and negative predictive value, respectively) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=see_link\">",
"     \"Acquired hypothyroidism in childhood and adolescence\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, the diagnosis of SCFE usually can be made on plain radiographs, which reveal an apparent posterior displacement of the femoral epiphysis, like ice cream slipping off a cone (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59157 \" href=\"UTD.htm?18/50/19235\">",
"     image 1",
"    </a>",
"    ). The earliest plain radiographic changes are widening and irregularity of the physis, with thinning of the proximal epiphysis. These changes are best seen on lateral views [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/62\">",
"     62",
"    </a>",
"    ]. If the radiograph is normal but suspicion for early SCFE is high, MRI can demonstrate widening of the physis with surrounding edema, essentially diagnostic of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children with SCFE should be referred promptly to an orthopedic surgeon. Patients with acute (unstable) slips should be admitted to the hospital for treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20\">",
"     20",
"    </a>",
"    ]. Hospital admission and bed rest also may be necessary for patients with bilateral SCFE, whether acute or chronic. Patients with unilateral chronic (stable) slips also require urgent evaluation because of the risk of further slippage; they may be referred to an emergency department or an orthopedic surgeon experienced in treating children's hip problems. They must avoid bearing weight until they have undergone orthopedic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/39\">",
"     39",
"    </a>",
"    ]. The use of crutches or a wheelchair and bed rest is strongly recommended to prevent further slippage (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef82320 \" href=\"UTD.htm?39/1/39967\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The goals of treatment of SCFE are stabilization of the diseased physis to prevent further slippage and avoidance of complications [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/44\">",
"     44",
"    </a>",
"    ]. The treatment of SCFE is operative. The gold standard for stabilization, regardless of severity, is the use of a single cannulated screw placed in the center of the epiphysis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/39\">",
"     39",
"    </a>",
"    ]. Stabilization usually involves pinning in situ (ie, without attempt at reduction) because manipulation has been found to correlate with a poorer long-term prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/36,63\">",
"     36,63",
"    </a>",
"    ]. Closed reduction of an acute slip before pinning is controversial. Although screw fixation is the most commonly used and widely accepted treatment for SCFE, bone peg epiphysiodesis is an acceptable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/64\">",
"     64",
"    </a>",
"    ]. Decisions regarding timing of surgery and operative technique should be left to the discretion of the orthopedic surgeon. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Post-operative management usually includes a period of limited weight bearing with crutches or a walker. In bilateral cases, patients are taught to use a four-point gait (eg, the right crutch followed by the left leg, followed by the left crutch, followed by the right leg, etc). After six to eight weeks, crutches are discontinued, and regular activities are gradually resumed. Return to sports participation depends upon the residual limitation of motion, since most patients lose internal hip rotation.",
"   </p>",
"   <p>",
"    In selected cases with severe deformity, reconstructive surgery can be considered. A number of proximal femoral osteotomies have been proposed to correct excessive hip varus and extension. Because the risk of avascular necrosis is increased with more proximal femoral neck osteotomies, the most commonly performed reconstructive procedure is the intertrochanteric osteotomy of Southwick [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/65\">",
"     65",
"    </a>",
"    ]. Surgical dislocation is another technique that is coming into use; early results in experienced hands are promising [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Follow-up",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 30 to 60 percent of patients with unilateral SCFE at presentation eventually have SCFE in the contralateral hip [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/5-7\">",
"     5-7",
"    </a>",
"    ]. Patients with underlying endocrine disorders have an even higher risk of subsequent bilateral involvement (up to 100 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/7,68\">",
"     7,68",
"    </a>",
"    ]. In more than 80 percent of cases of sequential slips, the second slip occurs within 18 months of diagnosis of the first slip [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/4\">",
"     4",
"    </a>",
"    ]. Age at presentation of &lt;10 years in boys and &lt;12 years in girls has been associated with development of contralateral slip as has skeletal immaturity [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. Second slips are often asymptomatic. For this reason, prophylactic pinning of the opposite hip is considered an option by some surgeons [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, prophylactic pinning of the contralateral hip is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/73-75\">",
"     73-75",
"    </a>",
"    ]. Advocates of prophylactic pinning suggest second slips often are unstable, predisposing the patient to an increased risk of osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/72\">",
"     72",
"    </a>",
"    ]. Advocates of observation suggest that close follow-up permits early identification and treatment of contralateral SCFE and prevents unnecessary surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/74\">",
"     74",
"    </a>",
"    ]. Two decision analyses, using different underlying assumptions, reached different conclusions [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/71,76\">",
"     71,76",
"    </a>",
"    ]. Additional information is needed to more accurately predict which children with unilateral idiopathic SCFE are at increased risk for contralateral SCFE and to better quantify the risks and benefits of observation versus prophylactic pinning [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To prevent delay in diagnosis of the second slip in children who do not undergo prophylactic pinning, all patients with unilateral involvement, particularly those with endocrinopathies, should be followed closely by an orthopedic surgeon. The patient should be scheduled for repeat examinations of the contralateral hip during the first one to two years after initial diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/77\">",
"     77",
"    </a>",
"    ]. Close follow-up should continue until the child has finished growing. In addition, patients and parents should be instructed to seek medical attention immediately if they experience any symptoms of SCFE (eg, nonradiating, dull, aching pain in the hip, groin, thigh, or knee).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of SCFE include osteonecrosis of the femoral head and chondrolysis, both of which increase the risk of subsequent development of osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/78-80\">",
"     78-80",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Long-term outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Osteonecrosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteonecrosis (also called aseptic necrosis, avascular necrosis, and ischemic necrosis) of the femoral head is the most serious complication of SCFE and has the worst prognosis. The natural history of osteonecrosis after treatment for SCFE is one of gradual degenerative changes for which reconstructive surgery is often required [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of occurrence of osteonecrosis increases with increasing severity of the slip (",
"    <a class=\"graphic graphic_table graphicRef68411 \" href=\"UTD.htm?37/35/38459\">",
"     table 1",
"    </a>",
"    ), occurring in 15 percent of patients with acute slips [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/82\">",
"     82",
"    </a>",
"    ]. Avascular necrosis rarely occurs in untreated chronic slips since the gradual slipping process permits maintenance of blood supply to the caput through adaptation of the vasculature [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/83\">",
"     83",
"    </a>",
"    ]. However, it can be a complication of operative pinning (if the lateral epiphyseal artery, which supplies the superior weight-bearing portion of the femoral head, is injured during surgery) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unstable SCFE is an important predictor for the development of osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/82,84\">",
"     82,84",
"    </a>",
"    ], particularly if vascular injury occurs at the time of the slip [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/83\">",
"     83",
"    </a>",
"    ]. Anterior physeal separation at the time of the slip also appears to be associated with subsequent development of osteonecrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Osteonecrosis should be suspected when a patient with a history of SCFE complains of persistent pain and stiffness of the hip [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20\">",
"     20",
"    </a>",
"    ]. Early in the course of osteonecrosis, the bone scan may show decreased uptake in the femoral head, but later bone scans may show increased uptake as the necrotic bone is replaced with new bone. Osteonecrosis also may be apparent on plain radiographs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef69304 \" href=\"UTD.htm?19/5/19551\">",
"     image 3",
"    </a>",
"    ) or MRI. SCFE patients who develop or are suspected to have osteonecrosis should be referred to an orthopedic surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Chondrolysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chondrolysis, or narrowing of the joint space and loss of articular cartilage, can occur with an untreated SCFE or develop postoperatively. It is present in up to 7 percent of cases even before treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/78\">",
"     78",
"    </a>",
"    ]. It is more common among girls than boys and is particularly common among black girls, having occurred in 51 percent of black females in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/86\">",
"     86",
"    </a>",
"    ]. It also is more common among patients with prolonged immobilization and in whom the stabilizing pins penetrate into the joint [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical manifestations of chondrolysis include pain and flexion deformity of the hip, with restricted range of motion in all planes. Radiographs show regional osteoporosis, followed by narrowing of the articular cartilage. MRI demonstrates narrowing of the joint space and irregularity of the articular cartilage. Changes on bone scan (decreased activity in the physis) may precede changes on plain radiographs [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The course varies from spontaneous resolution to partial recovery to rapid destruction of the articular cartilage with fibrosis and ankylosis of the hip joint. SCFE patients who develop or are suspected of having chondrolysis should be referred to an orthopedic surgeon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of SCFE is related to the severity of slip (",
"    <a class=\"graphic graphic_table graphicRef68411 \" href=\"UTD.htm?37/35/38459\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/34,63\">",
"     34,63",
"    </a>",
"    ]. Mild slips are usually well tolerated. However, patients with a history of SCFE are at increased risk for premature development of osteoarthritis (degenerative arthritis) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/88\">",
"     88",
"    </a>",
"    ], and unrecognized SCFE is thought to be a common cause of osteoarthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/89\">",
"     89",
"    </a>",
"    ]. In patients without complications, osteoarthritis of the hip usually develops over a course of decades. The rate of osteoarthritis at 20- to 40-year follow-up and the incidence of osteonecrosis and chondrolysis increase with increasing severity of slip (",
"    <a class=\"graphic graphic_table graphicRef68411 \" href=\"UTD.htm?37/35/38459\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of severity of slip, reconstructive arthroplasty for degenerative changes may be needed for persistent symptoms. As an example, in an observational study of 146 patients with SCFE who underwent in situ pinning and had follow-up 2 to 43 years later, reconstructive surgery was needed for persistent symptoms, primarily pain, stiffness and functional limitation, in 12 percent of patients including patients with mild, moderate, or severe slips [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23209/abstract/90\">",
"     90",
"    </a>",
"    ]. Of patients not undergoing reconstructive surgery, approximately one-third had persistent mild pain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Slipped capital femoral epiphysis (SCFE) is characterized by a displacement of the capital femoral epiphysis from the femoral neck through the physeal plate. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The mean age of presentation is 12 years in girls and 13.5 years in boys, near the time of peak linear growth. The male-to-female ratio is approximately 1.5:1. Obesity is a significant risk factor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The two most common features of the presentation of SCFE are pain and altered gait. The classic presentation is that of an obese adolescent with a complaint of nonradiating, dull, aching pain in the hip, groin, thigh, or knee, and no history of preceding trauma. The pain is increased by physical activity and may be chronic or intermittent. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SCFE is traditionally classified into four patterns of presentation on the basis of intensity and duration of symptoms: preslip, acute, acute-on-chronic, and chronic. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Presentation patterns'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis of SCFE usually can be made on plain radiographs, which reveal an apparent posterior displacement of the femoral epiphysis, like ice cream slipping off a cone (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef59157 \" href=\"UTD.htm?18/50/19235\">",
"       image 1",
"      </a>",
"      ). The earliest plain radiographic changes are widening and irregularity of the physis, with thinning of the proximal epiphysis (",
"      <a class=\"graphic graphic_figure graphicRef55393 \" href=\"UTD.htm?0/41/656\">",
"       figure 3",
"      </a>",
"      ). These changes are best seen on lateral views. If the radiograph is normal but suspicion for early SCFE is high, MRI may demonstrate widening of the physis with surrounding edema, essentially diagnostic of the disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Radiologic evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The treatment of SCFE is operative. Children with SCFE should be referred promptly to an orthopedic surgeon; they must avoid bearing weight until they have undergone orthopedic evaluation. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Approximately 30 to 60 percent of patients with unilateral SCFE at presentation eventually have SCFE in the contralateral hip. To prevent delay in diagnosis of the second slip, all patients with unilateral involvement should be followed closely by an orthopedic surgeon until after the child has finished growing. Patients and parents should be instructed to seek medical attention immediately if they experience symptoms of SCFE (eg, nonradiating, dull, aching pain in the hip, groin, thigh, or knee). (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Follow-up'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The complications of SCFE include osteonecrosis of the femoral head and chondrolysis, both of which increase the risk of subsequent development of osteoarthritis. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of SCFE is related to the severity of the slip (",
"      <a class=\"graphic graphic_table graphicRef68411 \" href=\"UTD.htm?37/35/38459\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Long-term outcome'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/1\">",
"      Kocher MS, Bishop JA, Weed B, et al. Delay in diagnosis of slipped capital femoral epiphysis. Pediatrics 2004; 113:e322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/2\">",
"      Kelsey JL, Keggi KJ, Southwick WO. The incidence and distrubition of slipped capital femoral epiphysis in Connecticut and Southwestern United States. J Bone Joint Surg Am 1970; 52:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/3\">",
"      Jerre R, Karlsson J, Henrikson B. The incidence of physiolysis of the hip: a population-based study of 175 patients. Acta Orthop Scand 1996; 67:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/4\">",
"      Loder RT. The demographics of slipped capital femoral epiphysis. An international multicenter study. Clin Orthop Relat Res 1996; :8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/5\">",
"      Loder RT, Aronson DD, Greenfield ML. The epidemiology of bilateral slipped capital femoral epiphysis. A study of children in Michigan. J Bone Joint Surg Am 1993; 75:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/6\">",
"      H&auml;gglund G, Hansson LI, Ordeberg G, Sandstr&ouml;m S. Bilaterality in slipped upper femoral epiphysis. J Bone Joint Surg Br 1988; 70:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/7\">",
"      Wells D, King JD, Roe TF, Kaufman FR. Review of slipped capital femoral epiphysis associated with endocrine disease. J Pediatr Orthop 1993; 13:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/8\">",
"      Benson EC, Miller M, Bosch P, Szalay EA. A new look at the incidence of slipped capital femoral epiphysis in new Mexico. J Pediatr Orthop 2008; 28:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/9\">",
"      Murray AW, Wilson NI. Changing incidence of slipped capital femoral epiphysis: a relationship with obesity? J Bone Joint Surg Br 2008; 90:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/10\">",
"      Loder RT, Hensinger RN. Slipped capital femoral epiphysis associated with renal failure osteodystrophy. J Pediatr Orthop 1997; 17:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/11\">",
"      Loder RT, Hensinger RN, Alburger PD, et al. Slipped capital femoral epiphysis associated with radiation therapy. J Pediatr Orthop 1998; 18:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/12\">",
"      Burrow SR, Alman B, Wright JG. Short stature as a screening test for endocrinopathy in slipped capital femoral epiphysis. J Bone Joint Surg Br 2001; 83:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/13\">",
"      Rappaport EB, Fife D. Slipped capital femoral epiphysis in growth hormone-deficient patients. Am J Dis Child 1985; 139:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/14\">",
"      Blethen SL, Rundle AC. Slipped capital femoral epiphysis in children treated with growth hormone. A summary of the National Cooperative Growth Study experience. Horm Res 1996; 46:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/15\">",
"      Shaw ED, Beals RK. The hip joint in Down's syndrome. A study of its structure and associated disease. Clin Orthop Relat Res 1992; :101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/16\">",
"      Bonioli E, Bellini C, S&eacute;n&egrave;s FM, et al. Slipped capital femoral epiphysis associated with Rubinstein-Taybi syndrome. Clin Genet 1993; 44:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/17\">",
"      Loder RT, Greenfield ML. Clinical characteristics of children with atypical and idiopathic slipped capital femoral epiphysis: description of the age-weight test and implications for further diagnostic investigation. J Pediatr Orthop 2001; 21:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/18\">",
"      Loder RT, Starnes T, Dikos G. Atypical and typical (idiopathic) slipped capital femoral epiphysis. Reconfirmation of the age-weight test and description of the height and age-height tests. J Bone Joint Surg Am 2006; 88:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/19\">",
"      Della-Giustina K, Della-Giustina DA. Emergency department evaluation and treatment of pediatric orthopedic injuries. Emerg Med Clin North Am 1999; 17:895.",
"     </a>",
"    </li>",
"    <li>",
"     Tachdijan MO. Slipped capital femoral epiphysis. In: Clinical Pediatric Orthopedics: The Art of Diagnosis and Principles of Management, Appleton and Lange, Stamford 1997. p.223.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/21\">",
"      Koop S, Quanbeck D. Three common causes of childhood hip pain. Pediatr Clin North Am 1996; 43:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/22\">",
"      Weiner D. Pathogenesis of slipped capital femoral epiphysis: current concepts. J Pediatr Orthop B 1996; 5:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/23\">",
"      Feydy A, Carlier RY, Mompoint D, et al. Bilateral slipped capital femoral epiphysis occuring in an adult with acromegalic gigantism. Skeletal Radiol 1997; 26:188.",
"     </a>",
"    </li>",
"    <li>",
"     Morrissy RT. Slipped capital femoral epiphysis. In: Pediatric Orthopaedics, Morrisy RT.  (Ed), Lippincott, Philadelphia 1990. Vol 2, p.885.",
"    </li>",
"    <li>",
"     Tachdijan MO. Slipped capital femoral epiphysis. In: Pediatric Orthopedics, WB Saunders, Philadelphia 1990. Vol 2, p.1016.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/26\">",
"      Moreira JF, Neves MC, Lopes G, Gomes AR. Slipped capital femoral epiphysis. A report of 4 cases occurring in one family. Int Orthop 1998; 22:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/27\">",
"      H&auml;gglund G, Hansson LI. Slipped capital femoral epiphysis in three generations. Acta Orthop Scand 1986; 57:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/28\">",
"      H&auml;gglund G, Hansson LI, Sandstr&ouml;m S. Familial slipped capital femoral epiphysis. Acta Orthop Scand 1986; 57:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/29\">",
"      Ochsner PE, Razavi R, Schinzel A. [Slipped capital femoral epiphyses in ten members of one family: probably autosomal dominant transmission with variable penetrance (author's transl)]. Z Orthop Ihre Grenzgeb 1977; 115:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/30\">",
"      Jingushi S, Hara T, Sugioka Y. Deficiency of a parathyroid hormone fragment containing the midportion and 1,25-dihydroxyvitamin D in serum of patients with slipped capital femoral epiphysis. J Pediatr Orthop 1997; 17:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/31\">",
"      Kempers MJ, Noordam C, Rouw&eacute; CW, Otten BJ. Can GnRH-agonist treatment cause slipped capital femoral epiphysis? J Pediatr Endocrinol Metab 2001; 14:729.",
"     </a>",
"    </li>",
"    <li>",
"     Kay RM. Slipped capital femoral epiphysis. In: Lovell and Winter's Pediatric Orthopaedics, 6th, Morrissey RT, Weinstein SL.  (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1085.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/33\">",
"      Kallio PE, Paterson DC, Foster BK, Lequesne GW. Classification in slipped capital femoral epiphysis. Sonographic assessment of stability and remodeling. Clin Orthop Relat Res 1993; :196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/34\">",
"      Boyer DW, Mickelson MR, Ponseti IV. Slipped capital femoral epiphysis. Long-term follow-up study of one hundred and twenty-one patients. J Bone Joint Surg Am 1981; 63:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/35\">",
"      FAHEY JJ, O'BRIEN ET. ACUTE SLIPPED CAPITAL FEMORAL EPIPHYSIS: REVIEW OF THE LITERATURE AND REPORT OF TEN CASES. J Bone Joint Surg Am 1965; 47:1105.",
"     </a>",
"    </li>",
"    <li>",
"     Renshaw TS. Pediatric Orthopedics, WB Saunders, Philadelphia 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/37\">",
"      Matava MJ, Patton CM, Luhmann S, et al. Knee pain as the initial symptom of slipped capital femoral epiphysis: an analysis of initial presentation and treatment. J Pediatr Orthop 1999; 19:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/38\">",
"      Ledwith CA, Fleisher GR. Slipped capital femoral epiphysis without hip pain leads to missed diagnosis. Pediatrics 1992; 89:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/39\">",
"      Reynolds RA. Diagnosis and treatment of slipped capital femoral epiphysis. Curr Opin Pediatr 1999; 11:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/40\">",
"      Loder RT, O'Donnell PW, Didelot WP, Kayes KJ. Valgus slipped capital femoral epiphysis. J Pediatr Orthop 2006; 26:594.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/41\">",
"      Loder RT, Richards BS, Shapiro PS, et al. Acute slipped capital femoral epiphysis: the importance of physeal stability. J Bone Joint Surg Am 1993; 75:1134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/42\">",
"      Southwick WO. Osteotomy through the lesser trochanter for slipped capital femoral epiphysis. J Bone Joint Surg Am 1967; 49:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/43\">",
"      Causey AL, Smith ER, Donaldson JJ, et al. Missed slipped capital femoral epiphysis: illustrative cases and a review. J Emerg Med 1995; 13:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/44\">",
"      Uglow MG, Clarke NM. The management of slipped capital femoral epiphysis. J Bone Joint Surg Br 2004; 86:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/45\">",
"      S&oslash;balle K, Juhl M, H&oslash;gh JP. [Delayed diagnosis of epiphysiolysis capitis femoris]. Ugeskr Laeger 1990; 152:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/46\">",
"      BURROWS HJ. Slipped upper femoral epiphysis; characteristic of a hundred cases. J Bone Joint Surg Br 1957; 39-B:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/47\">",
"      Cowell HR. The significance of early diagnosis and treatment of slipping of the capital femoral epiphysis. Clin Orthop Relat Res 1966; 48:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/48\">",
"      Hubbard AM. Imaging of pediatric hip disorders. Radiol Clin North Am 2001; 39:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/49\">",
"      Bloomberg TJ, Nuttall J, Stoker DJ. Radiology in early slipped femoral capital epiphysis. Clin Radiol 1978; 29:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/50\">",
"      Steel HH. The metaphyseal blanch sign of slipped capital femoral epiphysis. J Bone Joint Surg Am 1986; 68:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/51\">",
"      KLEIN A, JOPLIN RJ, REIDY JA, HANELIN J. Roentgenographic features of slipped capital femoral epiphysis. Am J Roentgenol Radium Ther 1951; 66:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/52\">",
"      Cohen MS, Gelberman RH, Griffin PP, et al. Slipped capital femoral epiphysis: assessment of epiphyseal displacement and angulation. J Pediatr Orthop 1986; 6:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/53\">",
"      Guzzanti V, Falciglia F. Slipped capital femoral epiphysis: comparison of a roentgenographic method and computed tomography in determining slip severity. J Pediatr Orthop 1991; 11:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/54\">",
"      Lalaji A, Umans H, Schneider R, et al. MRI features of confirmed \"pre-slip\" capital femoral epiphysis: a report of two cases. Skeletal Radiol 2002; 31:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/55\">",
"      Umans H, Liebling MS, Moy L, et al. Slipped capital femoral epiphysis: a physeal lesion diagnosed by MRI, with radiographic and CT correlation. Skeletal Radiol 1998; 27:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/56\">",
"      Kallio PE, Lequesne GW, Paterson DC, et al. Ultrasonography in slipped capital femoral epiphysis. Diagnosis and assessment of severity. J Bone Joint Surg Br 1991; 73:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/57\">",
"      Magnano GM, Lucigrai G, De Filippi C, et al. Diagnostic imaging of the early slipped capital femoral epiphysis. Radiol Med 1998; 95:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/58\">",
"      Castriota-Scanderbeg A, Orsi E. Slipped capital femoral epiphysis: ultrasonographic findings. Skeletal Radiol 1993; 22:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/59\">",
"      Kallio PE, Mah ET, Foster BK, et al. Slipped capital femoral epiphysis. Incidence and clinical assessment of physeal instability. J Bone Joint Surg Br 1995; 77:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/60\">",
"      Parsch K, Weller S, Parsch D. Open reduction and smooth Kirschner wire fixation for unstable slipped capital femoral epiphysis. J Pediatr Orthop 2009; 29:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/61\">",
"      Mann DC, Weddington J, Richton S. Hormonal studies in patients with slipped capital femoral epiphysis without evidence of endocrinopathy. J Pediatr Orthop 1988; 8:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/62\">",
"      Busch MT, Morrissy RT. Slipped capital femoral epiphysis. Orthop Clin North Am 1987; 18:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/63\">",
"      Carney BT, Weinstein SL, Noble J. Long-term follow-up of slipped capital femoral epiphysis. J Bone Joint Surg Am 1991; 73:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/64\">",
"      Adamczyk MJ, Weiner DS, Hawk D. A 50-year experience with bone graft epiphysiodesis in the treatment of slipped capital femoral epiphysis. J Pediatr Orthop 2003; 23:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/65\">",
"      Crawford AH. Role of osteotomy in the treatment of slipped capital femoral epiphysis. J Pediatr Orthop B 1996; 5:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/66\">",
"      Leunig M, Slongo T, Ganz R. Subcapital realignment in slipped capital femoral epiphysis: surgical hip dislocation and trimming of the stable trochanter to protect the perfusion of the epiphysis. Instr Course Lect 2008; 57:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/67\">",
"      Spencer S, Millis MB, Kim YJ. Early results of treatment of hip impingement syndrome in slipped capital femoral epiphysis and pistol grip deformity of the femoral head-neck junction using the surgical dislocation technique. J Pediatr Orthop 2006; 26:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/68\">",
"      Loder RT, Wittenberg B, DeSilva G. Slipped capital femoral epiphysis associated with endocrine disorders. J Pediatr Orthop 1995; 15:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/69\">",
"      Riad J, Bajelidze G, Gabos PG. Bilateral slipped capital femoral epiphysis: predictive factors for contralateral slip. J Pediatr Orthop 2007; 27:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/70\">",
"      Popejoy D, Emara K, Birch J. Prediction of contralateral slipped capital femoral epiphysis using the modified Oxford bone age score. J Pediatr Orthop 2012; 32:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/71\">",
"      Schultz WR, Weinstein JN, Weinstein SL, Smith BG. Prophylactic pinning of the contralateral hip in slipped capital femoral epiphysis : evaluation of long-term outcome for the contralateral hip with use of decision analysis. J Bone Joint Surg Am 2002; 84-A:1305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/72\">",
"      MacLean JG, Reddy SK. The contralateral slip. An avoidable complication and indication for prophylactic pinning in slipped upper femoral epiphysis. J Bone Joint Surg Br 2006; 88:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/73\">",
"      Kocher MS, Sarwark JF, Council of Musculoskeletal Specialty Societies of the American Academy of Orthopaedic Surgeons. What's new in pediatric orthopaedics. J Bone Joint Surg Am 2004; 86-A:1337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/74\">",
"      Castro FP Jr, Bennett JT, Doulens K. Epidemiological perspective on prophylactic pinning in patients with unilateral slipped capital femoral epiphysis. J Pediatr Orthop 2000; 20:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/75\">",
"      Loder RT. Controversies in slipped capital femoral epiphysis. Orthop Clin North Am 2006; 37:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/76\">",
"      Kocher MS, Bishop JA, Hresko MT, et al. Prophylactic pinning of the contralateral hip after unilateral slipped capital femoral epiphysis. J Bone Joint Surg Am 2004; 86-A:2658.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/77\">",
"      Loder RT. Slipped capital femoral epiphysis in children. Curr Opin Pediatr 1995; 7:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/78\">",
"      Lubicky JP. Chondrolysis and avascular necrosis: complications of slipped capital femoral epiphysis. J Pediatr Orthop B 1996; 5:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/79\">",
"      Hoaglund FT, Steinbach LS. Primary osteoarthritis of the hip: etiology and epidemiology. J Am Acad Orthop Surg 2001; 9:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/80\">",
"      Goodman DA, Feighan JE, Smith AD, et al. Subclinical slipped capital femoral epiphysis. Relationship to osteoarthrosis of the hip. J Bone Joint Surg Am 1997; 79:1489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/81\">",
"      Krahn TH, Canale ST, Beaty JH, et al. Long-term follow-up of patients with avascular necrosis after treatment of slipped capital femoral epiphysis. J Pediatr Orthop 1993; 13:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/82\">",
"      Rattey T, Piehl F, Wright JG. Acute slipped capital femoral epiphysis. Review of outcomes and rates of avascular necrosis. J Bone Joint Surg Am 1996; 78:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/83\">",
"      Maeda S, Kita A, Funayama K, Kokubun S. Vascular supply to slipped capital femoral epiphysis. J Pediatr Orthop 2001; 21:664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/84\">",
"      Kennedy JG, Hresko MT, Kasser JR, et al. Osteonecrosis of the femoral head associated with slipped capital femoral epiphysis. J Pediatr Orthop 2001; 21:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/85\">",
"      Ballard J, Cosgrove AP. Anterior physeal separation. A sign indicating a high risk for avascular necrosis after slipped capital femoral epiphysis. J Bone Joint Surg Br 2002; 84:1176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/86\">",
"      Ingram AJ, Clarke MS, Clarke CS Jr, Marshall WR. Chondrolysis complicating slipped capital femoral epiphysis. Clin Orthop Relat Res 1982; :99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/87\">",
"      Mandell GA, Keret D, Harcke HT, Bowen JR. Chondrolysis: detection by bone scintigraphy. J Pediatr Orthop 1992; 12:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/88\">",
"      Carney BT, Weinstein SL. Natural history of untreated chronic slipped capital femoral epiphysis. Clin Orthop Relat Res 1996; :43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/89\">",
"      Harris WH. Etiology of osteoarthritis of the hip. Clin Orthop Relat Res 1986; :20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23209/abstract/90\">",
"      Larson AN, Sierra RJ, Yu EM, et al. Outcomes of slipped capital femoral epiphysis treated with in situ pinning. J Pediatr Orthop 2012; 32:125.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6554 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-CCD5015BA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23209=[""].join("\n");
var outline_f22_42_23209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Presentation patterns",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Preslip",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Acute",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Acute-on-chronic",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Chronic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Severity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Radiologic evaluation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Plain radiographs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Other studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Additional tests",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Osteonecrosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Chondrolysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"EM/6554\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6554|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?18/50/19235\" title=\"diagnostic image 1\">",
"      SCFE radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/1/39967\" title=\"diagnostic image 2\">",
"      SCFE progression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?19/5/19551\" title=\"diagnostic image 3\">",
"      Osteonecrosis femoral head",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6554|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/5/6224\" title=\"figure 1\">",
"      Gait cycle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/10/6304\" title=\"figure 2\">",
"      SCFE epiphyseal shaft angle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/41/656\" title=\"figure 3\">",
"      SCFE metaphyseal blurring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?36/23/37247\" title=\"figure 4\">",
"      SCFE Blanch sign of Steel",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/8/31887\" title=\"figure 5\">",
"      SCFE Kleins line",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6554|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?2/50/2853\" title=\"picture 1\">",
"      Trendelenburg gait",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"EM/6554|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/35/38459\" title=\"table 1\">",
"      SCFE outcome by severity",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21865?source=related_link\">",
"      Acquired hypothyroidism in childhood and adolescence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/4/42057?source=related_link\">",
"      Approach to the child with a limp",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/50/37674?source=related_link\">",
"      Comorbidities and complications of obesity in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_42_23210="Pathogenesis of type 1 diabetes mellitus";
var content_f22_42_23210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis of type 1 diabetes mellitus",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23210/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23210/contributors\">",
"     Massimo Pietropaolo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23210/contributors\">",
"     Irl B Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?22/42/23210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?22/42/23210/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?22/42/23210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1A diabetes mellitus results from autoimmune destruction of the insulin-producing beta cells in the islets of Langerhans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/1\">",
"     1",
"    </a>",
"    ]. This process occurs in genetically susceptible subjects, is probably triggered by one or more environmental agents, and usually progresses over many months or years during which the subject is asymptomatic and euglycemic. Thus, genetic markers for type 1A diabetes are present from birth, immune markers are detectable after the onset of the autoimmune process, and metabolic markers can be detected with sensitive tests once enough &szlig;-cell damage has occurred, but before the onset of symptomatic hyperglycemia [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/2\">",
"     2",
"    </a>",
"    ]. This long latent period is a reflection of the large number of functioning beta cells that must be lost before hyperglycemia occurs (",
"    <a class=\"graphic graphic_figure graphicRef66417 \" href=\"UTD.htm?20/12/20686\">",
"     figure 1",
"    </a>",
"    ). Type 1B diabetes mellitus refers to non-autoimmune islet destruction (Type 1B diabetes). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=see_link\">",
"     \"Classification of diabetes mellitus and genetic diabetic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of type 1A diabetes is quite different from that of type 2 diabetes mellitus, in which both decreased insulin release (not on an autoimmune basis) and insulin resistance play an important role. Genome-wide association studies indicate that type 1 and type 2 diabetes genetic loci do not overlap, although inflammation (eg, interleukin-1 mediated) may play a role in islet beta cell loss in both types [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=see_link\">",
"     \"Pathogenesis of type 2 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis of type 1 diabetes mellitus will be reviewed here. The diagnosis and management of type 1 diabetes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=see_link\">",
"     \"Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=see_link\">",
"     \"Prevention of type 1 diabetes mellitus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=see_link\">",
"     \"Management of type 1 diabetes mellitus in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31414?source=see_link\">",
"     \"Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENETIC SUSCEPTIBILITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Polymorphisms of multiple genes are reported to influence the risk of type 1A diabetes (including, HLA-DQalpha, HLA-DQbeta, HLA-DR, preproinsulin, the PTPN22 gene, CTLA-4, interferon-induced helicase, IL2 receptor (CD25), a lectin-like gene (KIA0035), ERBB3e, and undefined gene at 12q) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/4-10\">",
"     4-10",
"    </a>",
"    ]. A meta-analysis of data from genome-wide association studies confirmed the above associations and identified four additional risk loci (BACH2, PRKCQ, CTSH, C1QTNF6) associated with an increased risk of type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, some loci conferring shared risk for celiac disease (RGS1, IL18RAP, CCR5, TAGAP, SH2B3, PTPN2) have been identified [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/12\">",
"     12",
"    </a>",
"    ]. Most loci have small effects, and the variants studied are common. The CCR5 association is of interest in that a 32-base pair insertion deletion in a chemokine receptor, CCR5, results in a loss of function and, when homozygous, a twofold decrease in risk of type 1 diabetes. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'MHC genes'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H4\">",
"     'Non-MHC genes'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H14\">",
"     'Association with other autoimmune diseases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Genes in both the major histocompatibility complex (MHC) and elsewhere in the genome influence risk, but only HLA alleles have a large effect, followed by insulin gene polymorphisms and PTPNN22. Although the association of certain HLA alleles with type 1 diabetes is strong, this genetic locus is estimated to account for less than 50 percent of genetic contributions to disease susceptibility. The associations of other loci are of a magnitude that do not contribute to prediction of disease but may implicate important pathways, such as CCR5.",
"   </p>",
"   <p>",
"    In particular, it is estimated that 48 percent of the familial aggregation can now be ascribed to known loci, and the major histocompatibility complex contributes 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/6\">",
"     6",
"    </a>",
"    ]. As an example, siblings with the highest risk HLA DR and DQ alleles (eg,",
"    <span class=\"nowrap\">",
"     DR3/DR4",
"    </span>",
"    heterozygotes), who inherit both HLA regions identical by descent to their diabetic sibling, may have a risk of developing anti-islet autoimmunity as high as 80 percent and a similar long-term risk of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lifelong risk of type 1 diabetes is markedly increased in close relatives of a patient with type 1 diabetes, averaging about 6 percent in offspring, 5 percent in siblings, and 50 percent in identical twins (versus 0.4 percent in subjects with no family history) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/1,14,15\">",
"     1,14,15",
"    </a>",
"    ]. A monozygotic twin of a patient with type 1 diabetes has a higher risk of diabetes than a dizygotic twin, and the risk in a dizygotic twin sibling is similar to that in non-twin siblings [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     MHC genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major susceptibility genes for type 1 diabetes (called IDDM1 for the MHC locus) are in the HLA region on chromosome 6p [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. This region contains genes that code for MHC class II molecules expressed on the cell surface of antigen-presenting cells such as macrophages. These MHC molecules consist of alpha and beta chains that form a peptide-binding groove in which antigens involved in the pathogenesis of type 1 diabetes are bound. MHC binding of antigen allows it to be presented to antigen receptors on T cells, which are the main effector cells of the destructive autoimmune process (",
"    <a class=\"graphic graphic_figure graphicRef63541 \" href=\"UTD.htm?6/23/6527\">",
"     figure 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=see_link\">",
"     \"Major histocompatibility complex (MHC) structure and function\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The ability of these class II molecules to present antigens is dependent in part upon the amino-acid composition of their alpha and beta chains. Substitutions at one or two critical positions can markedly increase or decrease binding of relevant autoantigens and therefore the susceptibility to type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. In particular, more than 90 percent of patients with type 1 diabetes carry either HLA-DR3,DQB1*0201 (also referred to as DR3-DQ2) or -DR4,DQB1*0302 (also referred to as DR4-DQ8), versus 40 percent of controls with either haplotype; furthermore, about 30 percent of patients have both haplotypes",
"    <span class=\"nowrap\">",
"     (DR3/4",
"    </span>",
"    heterozygotes), which confers the greatest susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of this high-risk genotype is remarkably high in some populations. As an example, 8.9 percent of healthy white teenagers in Washington state have the",
"    <span class=\"nowrap\">",
"     DR4,DQB1*0302/DR3,DQB1*0201",
"    </span>",
"    genotype and 2.4 percent of the general population of Denver, Colorado. Approximately 5 percent of children with this genotype develop type 1A diabetes versus approximately 0.3 percent of children overall [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. A subset of DR4 alleles, such as DRB1*0403 and DPB1*0402, decrease the risk of development of diabetes, even with the high risk DQB1*0302 allele [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, the HLA allele DQB1*0602 confers protection against the development of type 1 diabetes. This allele is present in approximately 20 percent of the general US population, but only 1 percent of children developing type 1A diabetes. One prospective study evaluated 72 relatives with islet-cell antibodies (ICA), 75 percent of whom carried the high-risk alleles DQB1*0302",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    *0201 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/23\">",
"     23",
"    </a>",
"    ]. Diabetes developed in 28 of the 64 subjects who did not have the DQB1*0602 allele versus none of the eight with it. No other common DQ allele provides such dramatic protection.",
"   </p>",
"   <p>",
"    The prevalence of these genes varies with ethnicity, and explains to a large degree why type 1 diabetes is relatively common in Scandinavia and Sardinia, but uncommon in China (",
"    <a class=\"graphic graphic_figure graphicRef80483 \" href=\"UTD.htm?28/47/29437\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Non-MHC genes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although important, the MHC susceptibility genes are not sufficient to induce type 1 diabetes, suggesting polygenic inheritance in most cases [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/16\">",
"     16",
"    </a>",
"    ]. An important component of the susceptibility to type 1 diabetes resides in certain non-MHC genes that have an effect only in the presence of the appropriate MHC alleles.",
"   </p>",
"   <p>",
"    In particular, polymorphisms of a promoter of the insulin gene and an amino acid change of a lymphocyte-specific tyrosine phosphatase (termed lyp, PTPN22) are associated with the risk of type 1 diabetes in multiple populations [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. A repeat sequence in the 5' region of the insulin gene is associated with greater insulin expression in the thymus and it is hypothesized that this contributes to decreasing the development of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/28\">",
"     28",
"    </a>",
"    ]. The polymorphism of the PTP gene influences T cell receptor signaling, and the same polymorphism is a major risk factor for multiple autoimmune disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/29,30\">",
"     29,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A polymorphism in the cytotoxic T-lymphocyte-associated antigen-4 gene was shown to be associated with the risk of type 1 diabetes in a meta-analysis of 33 studies involving over 5000 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional evidence for the role of non-MHC genes comes from studies in NOD mice (non-obese diabetic mice, a major model of type 1A diabetes). These mice develop spontaneous autoimmune diabetes with striking similarities to type 1 diabetes in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/32\">",
"     32",
"    </a>",
"    ]. Autoimmune infiltration of the islets of Langerhans (insulitis) begins at about 50 days of age and clinical diabetes appears at about 120 days.",
"   </p>",
"   <p>",
"    Interferon gamma-positive T cells (Th1 cells) appear to be an important mediator of the insulitis in NOD mice, and destruction of the islet cells can be slowed by the administration of anti-interferon gamma antibodies. Interferon gamma-inducing factor (IGIF; also called interleukin-18) and interleukin-12 are potent inducers of interferon gamma, and the progression of insulitis begins in parallel with increased release of these two cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It was initially thought that, in contrast to Th1 cells, Th2 cells (which produce interleukin-4, -5, -10, and -13) protected against the onset and progression of type 1 diabetes. However, Th2 cells also are capable of inducing islet-cell destruction and, therefore, the onset and progression of type 1 diabetes are probably under the control of both Th1 and Th2 cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more generalizable concept is that type 1A diabetes is prevented by a balance between pathogenic and regulatory T lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/35\">",
"     35",
"    </a>",
"    ]. A major subset of regulatory T lymphocytes have the markers CD4 and CD25 on their surface and lack the IL7 receptor, and are dependent for development upon a transcription factor termed foxP3. Mutations of foxP3 lead to lethal neonatal autoimmunity, including type 1 diabetes in neonates. This condition though extremely rare (IPEX syndrome: Immune dysfunction, polyendocrinopathy, enteropathy, X-linked) is important to recognize as bone marrow transplantation can reverse it [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/36\">",
"     36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3992?source=see_link&amp;anchor=H11#H11\">",
"     \"Overview of autoimmunity\", section on 'Pathogenetic mechanisms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     AUTOIMMUNITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Islet cell autoantibodies (ICAs) were first detected in serum from patients with autoimmune polyendocrine deficiency; they have subsequently been identified in 85 percent of patients with newly diagnosed type 1 diabetes and in prediabetic subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/1\">",
"     1",
"    </a>",
"    ]. Radioassays are available to detect autoantibodies which react with specific islet autoantigens. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=see_link\">",
"     \"Prediction of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Children with type 1 diabetes who do not have islet-cell or other autoantibodies at presentation have a similar degree of metabolic decompensation as do children who have these antibodies, although those with more of the different types of antibodies appear to have the most accelerated islet destruction and a higher requirement for exogenous insulin during the second year of clinical disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/37\">",
"     37",
"    </a>",
"    ]. A few patients from Japan without obvious evidence of islet autoimmunity have been described in whom the onset of hyperglycemia was abrupt, A1C (glycosylated hemoglobin values) were normal, and serum pancreatic enzyme concentrations were high [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/38\">",
"     38",
"    </a>",
"    ]. It is not clear whether these patients had an unusually abrupt onset of autoimmune type 1A diabetes or non-autoimmune islet destruction (type 1B diabetes), though with studies indicating high risk HLA alleles in these individuals, rapid type 1A diabetes in the absence of islet autoantibodies is a possibility.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Target autoantigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ongoing search has identified several autoantigens within the pancreatic &szlig;-cells that may play important roles in the initiation or progression of autoimmune islet injury (",
"    <a class=\"graphic graphic_table graphicRef69086 \" href=\"UTD.htm?0/13/219\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/1,39\">",
"     1,39",
"    </a>",
"    ]. Studies on the NOD (non-obese diabetic) mouse model indicate that",
"    <span class=\"nowrap\">",
"     proinsulin/insulin",
"    </span>",
"    itself is the likely primary target for the autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/40,41\">",
"     40,41",
"    </a>",
"    ]. The autoimmune response to proinsulin subsequently spreads to other autoantigens, such as islet-specific glucose-6-phosphatase catalytic-subunit-related protein (IGRP), which is downstream of the immune response to insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/41\">",
"     41",
"    </a>",
"    ]. Diabetes in the NOD mouse can be eliminated by changing a specific amino acid of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other important autoantigens are glutamic-acid decarboxylase (GAD), insulinoma-associated protein 2 (IA-2 and IA-2 beta), and the autoantigen ZnT8, a zinc transporter of islet beta cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/42-45\">",
"     42-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=see_link&amp;anchor=H7#H7\">",
"     \"Prediction of type 1 diabetes mellitus\", section on 'Immunologic markers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Insulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The early appearance of anti-insulin antibodies suggests that insulin is an important autoantigen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. Direct confirmation of this hypothesis has come from studies in NOD mice. Pathogenic CD8+ T cell clone recognizes an epitope on the insulin B chain [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/48\">",
"     48",
"    </a>",
"    ] and a major target autoantigen for CD4 T cells of NOD mice is insulin peptide B chain amino acids 9 to 23 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/40\">",
"     40",
"    </a>",
"    ]. Similar T-cell responses are found in peripheral lymphocytes obtained from patients with recent-onset type 1 diabetes and from subjects at high risk for the disease have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Also consistent with the importance of insulin as an autoantigen is the demonstration that knockouts of the insulin genes in NOD mice greatly influence progression to disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/50\">",
"     50",
"    </a>",
"    ], and the administration of insulin or its B chain during the prediabetic phase can prevent or delay diabetes in susceptible mice and perhaps in humans. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=see_link&amp;anchor=H10#H10\">",
"     \"Prevention of type 1 diabetes mellitus\", section on 'Insulin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Insulin autoantibodies are often the first to appear in children followed from birth and progressing to diabetes, and are the highest in young children developing diabetes. Of note, once insulin is administered subcutaneously, essentially all individuals develop insulin antibodies, and thus insulin autoantibody measurements after approximately two weeks of insulin injections cannot be used as a marker of immune mediated diabetes (type 1A) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Glutamic acid decarboxylase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another important autoantigen against which antibodies are detected is the enzyme glutamic acid decarboxylase (GAD), which is present in the islets as well as in the central nervous system and testes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/42\">",
"     42",
"    </a>",
"    ]. Antibodies to GAD (a 65-kD protein) are found in about 70 percent of patients with type 1 diabetes at the time of diagnosis.",
"   </p>",
"   <p>",
"    Autoantibodies reacting with GAD (anti GAD65 antibodies) are prominent in humans with type 1 diabetes. In contrast, the NOD mouse does not appear to express GAD autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/51\">",
"     51",
"    </a>",
"    ] but does express insulin autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/52\">",
"     52",
"    </a>",
"    ]. NOD mice rendered tolerant to GAD develop diabetes. This coupled with lack of GAD expression by mouse islets has cast doubt on its importance as a pathogenic autoantigen in this model, although injections of GAD peptides slow progression to diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Insulinoma-associated protein 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another autoantigen is a neuroendocrine protein called insulinoma-associated protein 2 (IA-2), which is a protein tyrosine phosphatase-related protein [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. IA-2 is granule membrane protein, whose cytosolic domain binds beta 2-syntrophin, an F-actin-associated protein, and is cleaved upon granule exocytosis. The resulting cleaved cytosolic fragment, ICA512-CCF, reaches the nucleus and upregulates the transcription of granule genes, including insulin and ICA512 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/54\">",
"     54",
"    </a>",
"    ]. In one study, antibodies to this antigen were found in the serum of 58 percent of patients with type 1 diabetes at the time of diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/55\">",
"     55",
"    </a>",
"    ]. Autoantibodies to IA-2 usually appear later than autoantibodies to insulin and GAD, and are highly associated with expression of multiple anti-islet autoantibodies and progression to diabetes. One of the best predictors of progression to type 1A diabetes is expression of two or three autoantibodies: GAD, IA-2 or insulin autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Zinc transporter ZnT8",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cation efflux zinc transporter (ZnT8) has also been identified as a candidate type 1 diabetes autoantigen [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/45\">",
"     45",
"    </a>",
"    ]. Sixty to 80 percent of patients with newly diagnosed type 1 diabetes have ZnT8 autoantibodies. In addition, 26 percent of subjects with antibody negative (insulin, GAD, IA-2 and ICA) type 1 diabetes have ZnT8 autoantibodies. In children followed from birth to the development of diabetes in the DAISY study, ZnT8 autoantibodies appear later than insulin autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/45\">",
"     45",
"    </a>",
"    ], and the antibody is typically lost very early after the onset of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H414416\">",
"    <span class=\"h3\">",
"     Other type 1 diabetes-related autoantigens",
"    </span>",
"    &nbsp;&mdash;&nbsp;As autoimmunity in T1D progresses from initial activation to a chronic state, there is often an increase in the number of islet autoantigens targeted by T cells and autoantibodies. This condition is termed &ldquo;epitope spreading.&rdquo; Several observations indicate that islet autoantibody responses directed to multiple islet autoantigens are associated with progression to overt disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/56\">",
"     56",
"    </a>",
"    ]. A number of additional T1D-related autoantigens have been identified, which include islet cell autoantigen 69 kDa (ICA69), the islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), chromogranin A (ChgA) the insulin receptor, heat shock proteins, the antigens jun-B,16, CD38, peripherin and glial fibrillary acidic protein (GFAP) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has been hypothesized that early autoimmunity in spontaneous type 1 diabetes can also target nervous system tissue elements, raising the concept that in type 1 diabetes pathogenetic immune responses may also be non-&beta;-cell exclusive [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/59\">",
"     59",
"    </a>",
"    ]. However, it remains to be established as to whether or not the presence of serologic responses to putative neuronal antigens are predictive of the development of small fiber neuropathy (autonomic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    somatic) and for the progression to clinical type 1 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Role of cellular immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The existence of IgG immunoglobulins directed to epitopes of islet autoantigens implies the influence of T cell participation in the autoimmune response. While the role of autoimmunity in the pathogenesis of type 1 diabetes and the frequent development of autoantibodies are not in question, there is increasing evidence for a major role of cellular immunity. The occurrence of type 1 diabetes in a 14-year-old boy with X-linked agammaglobulinemia suggests that B cells are not required for the development of the disorder and that the destruction of pancreatic beta cells is mediated principally by T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The observation that this boy did not develop the disorder until age 14 years might imply that normal B cells facilitate the development of diabetes, but are not absolutely necessary. This is supported by a study of NOD mice, which found that when the mice were rendered absolutely deficient in B cells, the incidence of diabetes in female mice dropped from 80 percent to 30 percent, and the disease developed later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/61\">",
"     61",
"    </a>",
"    ]. Other groups have reported almost complete protection if autoantibodies are absent [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Naturally processed epitopes of islet cell autoantigens represent the targets of effector and regulatory T cells in controlling pancreatic beta cell specific autoimmune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/63\">",
"     63",
"    </a>",
"    ]. In particular, naturally processed HLA class II allele-specific epitopes recognized by CD4",
"    <sup>",
"     +",
"    </sup>",
"    T cells, corresponding to the intracellular domain of IA-2, were identified after native IA-2 antigen was delivered to EBV-transformed B cells and peptides eluted and analyzed by mass spectrometry [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/64\">",
"     64",
"    </a>",
"    ]. Furthermore, dendritic cell subsets can process and present soluble IA-2 to CD4",
"    <sup>",
"     +",
"    </sup>",
"    T-cells after short-term culture, but only plasmacytoid dendritic cells enhance (by as much as 100 percent) autoantigen presentation in the presence of IA-2 autoantibody patient serum [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/65\">",
"     65",
"    </a>",
"    ]. The plasmacytoid subset of dendritic cells is overrepresented in the blood close to type 1 diabetes onset and shows a distinctive ability to capture islet autoantigenic immune complexes and enhance autoantigen-driven CD4",
"    <sup>",
"     +",
"    </sup>",
"    T-cell activation. This suggests a synergistic proinflammatory role for plasmacytoid dendritic cells and IA-2 autoantibodies in type 1 diabetes. Taken together, these observations may lead to identification of novel naturally processed epitopes recognized by CD4",
"    <sup>",
"     +",
"    </sup>",
"    T cells, which may represent potential therapeutic agents, either in native form or as antagonistic altered peptide ligands, for the treatment of type 1 diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Molecular mimicry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initiating factors of the immune response are not well understood. One possibility is molecular mimicry due to homology between GAD and an infectious agent such as Coxsackie B virus. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Role of viruses'",
"    </a>",
"    below.) A study of the expression of a beta-cell specific 38 kDa protein in rats provides an alternative model for how this might occur [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/66\">",
"     66",
"    </a>",
"    ]. This protein is expressed in the islets at birth and at all times thereafter in strains that are resistant to the development of diabetes, but is not expressed until day 30 in diabetes-prone BB rats. Delayed expression of this protein may lead to loss of self-tolerance and the initiation of an anti-beta-cell autoimmune response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Reversal of diabetes in animal models",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reversal of type 1 diabetes with administration of complete Freund's adjuvant, an immune modulator, has been reported in up to 32 percent of treated diabetic mice [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]. This recovery is believed to be due to immunomodulation of an underlying autoimmune condition, allowing proliferation of small numbers of surviving islet cells and restoration of the beta cell mass in the mouse pancreas. A related adjuvant regimen used in human trials did not delay loss of C-peptide secretion and other immune modulators. The immunosuppressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil, anti-CD3 antibody, and anti-CD20 monoclonal antibody are under investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=see_link&amp;anchor=H2#H2\">",
"     \"Prevention of type 1 diabetes mellitus\", section on 'Prevention and reversal strategies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Association with other autoimmune diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The autoimmune response in type 1 diabetes may be accompanied by antibodies directed against other organs including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thyroid autoimmunity is particularly common amongst patients with type 1A diabetes, affecting more than one-fourth of individuals. We recommend annual testing of TSH in children to detect early thyroid metabolic abnormalities. If anti-thyroid autoantibodies are present (eg, anti-thyroid peroxidase), risk of hypothyroidism is greatly increased [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/72\">",
"       72",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Antiadrenal antibodies and adrenal insufficiency. In one report, 11 of 629 patients (1.7 percent) with type 1 diabetes but none of 239 normal subjects had antibodies directed against 21-hydroxylase, a common autoantigen in primary adrenal insufficiency [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/73\">",
"       73",
"      </a>",
"      ]. Three of eight patients with anti-21-hydroxylase antibodies had adrenal insufficiency. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9896?source=see_link\">",
"       \"Pathogenesis of autoimmune adrenal insufficiency\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polyglandular autoimmune disease, especially type II, in which adrenal insufficiency, autoimmune thyroid disease, and gonadal insufficiency are the other major components. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link\">",
"       \"Causes of primary adrenal insufficiency (Addison's disease)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transglutaminase autoantibodies are present in approximately 10 percent of patients, and half of these patients have high levels of the autoantibody and celiac disease on biopsy [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/74,75\">",
"       74,75",
"      </a>",
"      ]. In addition, certain alleles (eg, PTPN2, CTLA4, RGS1) confer a genetic susceptibility to both type 1 diabetes and celiac disease, suggesting a common biologic pathway [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/12\">",
"       12",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=see_link&amp;anchor=H3#H3\">",
"       \"Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults\", section on 'Genetic factors'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=see_link&amp;anchor=H11#H11\">",
"       \"Diagnosis of celiac disease\", section on 'Anti-tissue transglutaminase antibodies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Rare syndromes associated with type 1 diabetes have shed important light on pathogenesis. The IPEX syndrome is associated with neonates developing type 1 diabetes. These infants usually die of overwhelming autoimmunity, in particular, severe enteritis. They have a mutation of a gene termed foxp3, a \"master-switch\" for the development of regulatory T cells. Studies of the syndrome and the related animal model provide dramatic evidence that regulatory T cells (formerly termed suppressor T cells) have a major physiologic role. The APS-I syndrome (Autoimmune Polyendocrine Syndrome type 1) is caused by a mutation of the AIRE gene (autoimmune regulator). This gene controls expression of a series of \"peripheral\" antigens in the thymus, including insulin. It is thought that the gene provides protection from autoimmune disorders, including type 1 diabetes, via its influence on central T cell tolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental influences are another important factor in the development of type 1 diabetes. The best evidence for this influence is the demonstration in multiple populations of a rapid increase in the incidence of type 1A diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. The etiology of the increase is unknown. One hypothesis, termed the hygiene hypothesis, relates improved \"sanitation\" to increasing immune mediated disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/79\">",
"     79",
"    </a>",
"    ]. Twin studies indicate that not all monozygotic twins of probands with type 1 diabetes develop diabetes, although the cumulative prevalence increases with long-term follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/14,15,80\">",
"     14,15,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Perinatal factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several pregnancy-related and perinatal factors were associated with a small increase in risk of type 1 diabetes in a study of 892 children with diabetes and 2291 normal children in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/81\">",
"     81",
"    </a>",
"    ]. They were maternal age &gt;25 years, preeclampsia, neonatal respiratory disease, and jaundice, especially that due to ABO blood group incompatibility; protective factors were low birth weight and short birth length. One cohort study found a relatively weak but significant direct association between birth weight and risk of type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/82\">",
"     82",
"    </a>",
"    ]; in a second study, the association was limited to cases with disease onset prior to age 10 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/83\">",
"     83",
"    </a>",
"    ]. Postnatal dietary factors, such as vitamin D and omega-3 fatty acid ingestion may also be important [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Role of diet'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Role of viruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Viruses can cause diabetes in animal models either by directly infecting and destroying beta cells or by triggering an autoimmune attack against these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/85\">",
"     85",
"    </a>",
"    ]. Although isolated case reports have suggested direct viral destruction of beta cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/86\">",
"     86",
"    </a>",
"    ], this is probably extremely rare. A careful autopsy study found no evidence for acute or persisting infection from Coxsackie, Epstein-Barr virus, mumps, or cytomegalovirus in the pancreatic tissue of 75 patients who died within a few weeks of developing type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/87\">",
"     87",
"    </a>",
"    ]. However, some unusual forms of diabetes have been associated with the presence of Coxsackie virus in a large number of beta cells [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The importance of autoimmune activation is also uncertain. Coxsackie B virus-specific IgM responses have been found in 39 percent of children with newly diagnosed type 1 diabetes, compared with only 6 percent of normal children [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/89\">",
"     89",
"    </a>",
"    ]. Two additional findings were noted in another report [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/90\">",
"     90",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Coxsackie virus antibody titers were significantly higher in pregnant women whose children subsequently developed type 1 diabetes, compared with pregnant women whose children did not become diabetic.",
"     </li>",
"     <li>",
"      Enteroviral infections were almost two times more common in siblings who developed type 1 diabetes than in siblings who remained nondiabetic.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These observations suggest that exposure to enteroviruses, both in utero and in childhood, can induce beta cell damage and lead to clinical diabetes. Significant homology has been found between human GAD and the F2C protein of Coxsackievirus B4, suggesting a possible role for molecular mimicry [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility of viral-induced autoimmunity or molecular mimicry is supported by long-term follow-up of infants with the congenital rubella syndrome. Autoimmune diabetes and other autoimmune diseases may occur 5 to 20 years after infection, especially in those subjects who have HLA-DR3 [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/93,94\">",
"     93,94",
"    </a>",
"    ]. Unfortunately, the long latent period between peak immunologic activity and clinical disease means that measuring viral titers at the onset of hyperglycemia is unlikely to be helpful.",
"   </p>",
"   <p>",
"    The clearest association of viral infection with the development of spontaneous autoimmune diabetes comes from the observation that BB-DR rats, a diabetes resistant strain of rats related to BB rats but without the severe lymphopenia of BB rats, develop diabetes when infected with the Kilham rat virus [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/95\">",
"     95",
"    </a>",
"    ]. Studies suggest a role for innate immune system activation in this model. In a similar manner, poly-IC injections (a mimic of double stranded RNA viruses that induces interferon alpha secretion) can induce diabetes in this model and in a mouse model, where induction of interferon alpha is essential for diabetes development [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the above reports, there are data that refute the role of viruses in the pathogenesis of type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/97,98\">",
"     97,98",
"    </a>",
"    ]. In one report, Coxsackie B virus infections in childhood were associated with transient production of antibodies to GAD, but not type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To further confuse the issue, there is evidence that viruses may protect against type 1 diabetes. In NOD mice and BB rats inoculation with lymphocytic choriomeningitis virus at an early age reduced the incidence of diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/99,100\">",
"     99,100",
"    </a>",
"    ]. Also supporting a protective role for viruses is the observation that raising NOD mice and BB rats in pathogen-free environments leads to an increased incidence of type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Childhood immunization",
"    </span>",
"    &nbsp;&mdash;&nbsp;There has been concern that childhood vaccination may be associated with later development of chronic diseases, including type 1 diabetes. However, immunization of genetically pre-disposed infants (siblings with type 1 diabetes) with viral (and bacterial) antigens does not appear to be associated with an increased risk of developing type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=see_link&amp;anchor=H12#H12\">",
"     \"Autism and chronic disease: Little evidence for vaccines as a contributing factor\", section on 'Type 1 diabetes mellitus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Role of diet",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several dietary factors may influence the development of type 1 diabetes, with most attention having been paid to cow's milk [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/103\">",
"     103",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Cow's milk",
"    </span>",
"    &nbsp;&mdash;&nbsp;It has been proposed that some component of albumin in cow's milk (bovine serum albumin), the basis for most infant milk formulas, may trigger an autoimmune response [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/104\">",
"     104",
"    </a>",
"    ]. As an example, epidemiologic data from Finland suggest that there is an increased risk of type 1 diabetes associated with introduction to dairy products at an early age and with high milk consumption during childhood [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/104\">",
"     104",
"    </a>",
"    ]. However, a cross-sectional study found no evidence of an association between early exposure to cow's milk and the development of type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/105\">",
"     105",
"    </a>",
"    ], and some prospective studies have found no association between the duration of breast feeding or introduction of cow's milk and the development of islet autoimmunity in children at high risk of type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/97,106\">",
"     97,106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It has also been suggested that a cell-mediated response to a specific cow's milk protein, beta-casein, may be involved in the pathogenesis of type 1 diabetes. In one report, 36 patients with recent-onset type 1 diabetes were compared with 36 normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/107\">",
"     107",
"    </a>",
"    ]. Exposure to bovine beta-casein led to proliferation of peripheral blood T-cells in 51 percent of the patients with type 1 diabetes versus only one (3 percent) of the normal subjects. In addition, an epidemiological study of children from 10 countries revealed a strong correlation between the incidence of type 1 diabetes and the consumption of beta-casein [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A more detailed understanding of the complex protein composition of early cow's milk exposure is necessary to understand its effect upon the development of type 1 diabetes. Randomized trials of early nutritional intervention with formulas containing less complex dietary proteins are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=see_link&amp;anchor=H4173426#H4173426\">",
"     \"Prevention of type 1 diabetes mellitus\", section on 'Avoidance of cow's milk'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Vitamin D supplements",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although cow's milk may be associated with an increase of risk for type 1 diabetes, one component, vitamin D, may be protective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=see_link&amp;anchor=H21#H21\">",
"     \"Prevention of type 1 diabetes mellitus\", section on 'Vitamin D supplements'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Cereals",
"    </span>",
"    &nbsp;&mdash;&nbsp;In infants at high risk for type 1 diabetes, the timing of initial exposure to cereals may affect the risk of developing islet cell autoantibodies (IA). In two large prospective cohort studies of newborns at high risk for type 1 diabetes (either a first degree relative [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/109,110\">",
"     109,110",
"    </a>",
"    ] or a high risk HLA genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/109\">",
"     109",
"    </a>",
"    ]), first exposure to cereal before age three months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/109,110\">",
"     109,110",
"    </a>",
"    ] or after seven months [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/109\">",
"     109",
"    </a>",
"    ] was associated with an increased risk of developing IA compared with infants whose first exposure was between ages four to six months (hazard ratio [HR] 4.0-4.3 and 5.4, respectively). The increased risk was associated with gluten-containing cereals in one study [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/110\">",
"     110",
"    </a>",
"    ], but with either gluten or rice-containing cereals in the other [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/109\">",
"     109",
"    </a>",
"    ]. Early introduction of gluten (&lt;3 months of age) increases the risk of celiac disease [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/111\">",
"     111",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The actual future risk of type 1 diabetes in these infants is not known. Based upon these data, we do not recommend changing current infant feeding guidelines, which state that cereal should be introduced between ages four and six months. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=see_link&amp;anchor=H6#H6\">",
"     \"Introducing solid foods and vitamin and mineral supplementation during infancy\", section on 'Optimal timing'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Omega-3 fatty acids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Omega-3 fatty acids may be involved in the development of autoimmunity and type 1 diabetes. Preliminary studies in animals support a protective role of omega-3 fatty acids in the inflammatory response associated with autoimmune islet cell destruction [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/112,113\">",
"     112,113",
"    </a>",
"    ]. In a case-control study from Norway, children with type 1 diabetes were less likely to be given cod liver oil (containing omega-3 fatty acids and vitamin D) during infancy than children without diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/84\">",
"     84",
"    </a>",
"    ]. In addition, a longitudinal observational study of children at increased risk for type 1 diabetes reported an inverse association between omega-3 fatty acid intake and development of islet autoimmunity (adjusted HR 0.45, 95% CI 0.21-0.96) [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/114\">",
"     114",
"    </a>",
"    ]. A clinical trial of omega-3 fatty acid supplementation in infants with high genetic risk of type 1 diabetes is underway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=see_link&amp;anchor=H22#H22\">",
"     \"Prevention of type 1 diabetes mellitus\", section on 'Omega-3 polyunsaturated fatty acids'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of polyunsaturated fatty acids in the prevention of other diseases is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=see_link&amp;anchor=H14#H14\">",
"     \"Dietary fat\", section on 'Polyunsaturated fatty acids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Nitrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in Colorado and in Yorkshire (UK) have found that the incidence of type 1 diabetes correlates with the concentration of nitrates in the drinking water [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/115\">",
"     115",
"    </a>",
"    ]. The incidence is about 30 percent higher in areas with nitrate concentrations above 14.8",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    compared with areas with concentrations below 3.2",
"    <span class=\"nowrap\">",
"     mg/L.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     DETERMINANTS OF INSULIN DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although",
"    glucose tolerance can remain normal until near the onset of clinical type 1 diabetes, measurement of pancreatic beta cell function usually shows substantial reduction in insulin secretion during the preclinical period [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/116,117\">",
"     116,117",
"    </a>",
"    ]. Impaired glucose tolerance frequently precedes the onset of overt diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/118\">",
"     118",
"    </a>",
"    ]. The most widely used test to estimate functioning beta cell mass is measurement of the acute insulin response to an intravenous injection of glucose (AIRg). This test [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/119,120\">",
"     119,120",
"    </a>",
"    ] is used, along with immunologic measurements, to identify subjects at high risk for type 1 diabetes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=see_link\">",
"     \"Prediction of type 1 diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been thought in the past that about 90 percent of the beta cell mass needs to be destroyed before hyperglycemia occurs; however, this is probably not true. As an example, the administration of streptozotocin in increasing doses to adolescent baboons can induce complete insulin dependency (with no detectable AIRg) at a time when 30 to 50 percent of the beta cell mass is still viable [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/121\">",
"     121",
"    </a>",
"    ]. The profound insulin deficiency in this setting is out of proportion to the loss of functioning cells and may be due in part to the inhibitory action of cytokines released from inflammatory cells in the islets. The following observations are consistent with the importance of such external factors:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      When severely inflamed islets are removed from 12 to 13 week-old NOD mice and studied in culture, insulin secretion on day 0 is very low, but there is almost complete recovery of function by day seven (",
"      <a class=\"graphic graphic_figure graphicRef53657 \" href=\"UTD.htm?28/10/28845\">",
"       figure 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Histologic and in vitro physiologic studies of the pancreas of a patient who died soon after the onset of type 1 diabetes revealed that a substantial mass of beta cells were still viable [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/123\">",
"       123",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a mouse model of diphtheria toxin-induced beta cell apoptosis (characterized by the absence of an inflammatory reaction), cessation of diphtheria toxin expression was associated with beta cell proliferation, recovery of beta cell function, and subsequent normalization of glucose homeostasis, even in a hyperglycemic environment [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/124\">",
"       124",
"      </a>",
"      ]. These findings are in contrast to those observed in autoimmune and pharmacological (streptozotocin) models of diabetes, in which beta cells have demonstrated a poor ability to regenerate.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings are of potential clinical importance, because they suggest that severe hyperglycemia does not necessarily imply irreversible loss of almost all functioning beta cells. Thus, stopping the autoimmune process, even at this late stage, may allow substantial recovery of beta cell function.",
"   </p>",
"   <p>",
"    Insulin-like growth factor 1 (IGF-1) is thought to play a role in islet development and function. In transgenic mice, local expression of IGF-1 in beta cells resulted in regeneration of pancreatic islets and reversal of type 1 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/125\">",
"     125",
"    </a>",
"    ]. However, in another study, beta-cell-specific deletion of the IGF-1 receptor did not affect beta cell mass, but resulted in hyperinsulinemia and glucose intolerance [",
"    <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/126\">",
"     126",
"    </a>",
"    ]. This suggests that the IGF-1 receptor may not be critical for beta cell development, but is important for beta cell function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     CLINICAL RESEARCH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The National Institutes of Health has established a program termed Trialnet whose goal is the prevention of type 1A diabetes and prevention of further beta cell destruction in patients with recent onset diabetes. Relatives of patients with type 1A diabetes can be screened for expression of islet autoantibodies and trials are available to study agents to halt beta cell destruction in multiple centers throughout the United States and the world (",
"    <a class=\"external\" href=\"file://www.diabetestrialnet.org/\">",
"     www.diabetestrialnet.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=see_link\">",
"       \"Patient information: Type 1 diabetes (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=see_link\">",
"       \"Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 1A diabetes mellitus results from autoimmune destruction of the insulin-producing beta cells in the islets of Langerhans [",
"      <a class=\"abstract\" href=\"UTD.htm?22/42/23210/abstract/1\">",
"       1",
"      </a>",
"      ]. This process occurs in genetically susceptible subjects, is probably triggered by one or more environmental agents, and usually progresses over many months or years during which the subject is asymptomatic and euglycemic. This long latent period is a reflection of the large number of functioning beta cells that must be lost before hyperglycemia occurs (",
"      <a class=\"graphic graphic_figure graphicRef66417 \" href=\"UTD.htm?20/12/20686\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Polymorphisms of multiple genes are known to influence the risk of type 1A diabetes (HLA-Dqalpha; HLA-Dqbeta; HLA-DR, preproinsulin, the PTPN22 gene, and CTLA-4), with whole genome analysis providing additional genes and loci, such as KIAA0035 (a lectin). Genes in both the major histocompatibility complex (MHC) and elsewhere in the genome influence risk, but only HLA alleles have a large effect. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Genetic susceptibility'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are a number of autoantigens within the pancreatic beta cells that may play important roles in the initiation or progression of autoimmune islet injury including glutamic acid decarboxylase (GAD), insulin, insulinoma-associated protein 2 (IA-2), and zinc transporter ZnT8. It is not certain, however, which of these autoantigens is involved in the initiation of the injury and which are secondary, being released only after the injury, though in the NOD mouse model and man increasing evidence points to insulin as the primary immune target. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Target autoantigens'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=see_link\">",
"       \"Prediction of type 1 diabetes mellitus\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Environmental factors that may affect risk include pregnancy-related and perinatal influences, viruses, and ingestion of cow&rsquo;s milk and cereals. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Environmental factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8088213\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The author and UpToDate would like to acknowledge the late Dr. George S Eisenbarth, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/1\">",
"      Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331:1428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/2\">",
"      McCulloch DK, Palmer JP. The appropriate use of B-cell function testing in the preclinical period of type 1 diabetes. Diabet Med 1991; 8:800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/3\">",
"      Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/4\">",
"      Smyth DJ, Cooper JD, Bailey R, et al. A genome-wide association study of nonsynonymous SNPs identifies a type 1 diabetes locus in the interferon-induced helicase (IFIH1) region. Nat Genet 2006; 38:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/5\">",
"      Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447:661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/6\">",
"      Todd JA, Walker NM, Cooper JD, et al. Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/7\">",
"      Hakonarson H, Grant SF, Bradfield JP, et al. A genome-wide association study identifies KIAA0350 as a type 1 diabetes gene. Nature 2007; 448:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/8\">",
"      Lowe CE, Cooper JD, Brusko T, et al. Large-scale genetic fine mapping and genotype-phenotype associations implicate polymorphism in the IL2RA region in type 1 diabetes. Nat Genet 2007; 39:1074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/9\">",
"      Concannon P, Onengut-Gumuscu S, Todd JA, et al. A human type 1 diabetes susceptibility locus maps to chromosome 21q22.3. Diabetes 2008; 57:2858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/10\">",
"      Concannon P, Rich SS, Nepom GT. Genetics of type 1A diabetes. N Engl J Med 2009; 360:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/11\">",
"      Cooper JD, Smyth DJ, Smiles AM, et al. Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. Nat Genet 2008; 40:1399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/12\">",
"      Smyth DJ, Plagnol V, Walker NM, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 2008; 359:2767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/13\">",
"      Aly TA, Ide A, Jahromi MM, et al. Extreme genetic risk for type 1A diabetes. Proc Natl Acad Sci U S A 2006; 103:14074.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/14\">",
"      Redondo MJ, Rewers M, Yu L, et al. Genetic determination of islet cell autoimmunity in monozygotic twin, dizygotic twin, and non-twin siblings of patients with type 1 diabetes: prospective twin study. BMJ 1999; 318:698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/15\">",
"      Kaprio J, Tuomilehto J, Koskenvuo M, et al. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. Diabetologia 1992; 35:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/16\">",
"      Davies JL, Kawaguchi Y, Bennett ST, et al. A genome-wide search for human type 1 diabetes susceptibility genes. Nature 1994; 371:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/17\">",
"      Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996; 85:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/18\">",
"      Khalil I, d'Auriol L, Gobet M, et al. A combination of HLA-DQ beta Asp57-negative and HLA DQ alpha Arg52 confers susceptibility to insulin-dependent diabetes mellitus. J Clin Invest 1990; 85:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/19\">",
"      Rowe RE, Leech NJ, Nepom GT, McCulloch DK. High genetic risk for IDDM in the Pacific Northwest. First report from the Washington State Diabetes Prediction Study. Diabetes 1994; 43:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/20\">",
"      Barker JM, Barriga KJ, Yu L, et al. Prediction of autoantibody positivity and progression to type 1 diabetes: Diabetes Autoimmunity Study in the Young (DAISY). J Clin Endocrinol Metab 2004; 89:3896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/21\">",
"      Undlien DE, Friede T, Rammensee HG, et al. HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes 1997; 46:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/22\">",
"      Baschal EE, Aly TA, Babu SR, et al. HLA-DPB1*0402 protects against type 1A diabetes autoimmunity in the highest risk DR3-DQB1*0201/DR4-DQB1*0302 DAISY population. Diabetes 2007; 56:2405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/23\">",
"      Pugliese A, Gianani R, Moromisato R, et al. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 1995; 44:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/24\">",
"      Bell GI, Horita S, Karam JH. A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. Diabetes 1984; 33:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/25\">",
"      Barratt BJ, Payne F, Lowe CE, et al. Remapping the insulin gene/IDDM2 locus in type 1 diabetes. Diabetes 2004; 53:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/26\">",
"      Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet 2004; 36:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/27\">",
"      Smyth D, Cooper JD, Collins JE, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes 2004; 53:3020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/28\">",
"      Pugliese A. Genetics of type 1 diabetes. Endocrinol Metab Clin North Am 2004; 33:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/29\">",
"      Begovich AB, Carlton VE, Honigberg LA, et al. A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. Am J Hum Genet 2004; 75:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/30\">",
"      Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet 2004; 75:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/31\">",
"      Kavvoura FK, Ioannidis JP. CTLA-4 gene polymorphisms and susceptibility to type 1 diabetes mellitus: a HuGE Review and meta-analysis. Am J Epidemiol 2005; 162:3.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/32\">",
"      Kolb H. Mouse models of insulin dependent diabetes: low-dose streptozocin-induced diabetes and nonobese diabetic (NOD) mice. Diabetes Metab Rev 1987; 3:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/33\">",
"      Rothe H, Jenkins NA, Copeland NG, Kolb H. Active stage of autoimmune diabetes is associated with the expression of a novel cytokine, IGIF, which is located near Idd2. J Clin Invest 1997; 99:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/34\">",
"      Almawi WY, Tamim H, Azar ST. Clinical review 103: T helper type 1 and 2 cytokines mediate the onset and progression of type I (insulin-dependent) diabetes. J Clin Endocrinol Metab 1999; 84:1497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/35\">",
"      Bluestone JA, Tang Q. Therapeutic vaccination using CD4+CD25+ antigen-specific regulatory T cells. Proc Natl Acad Sci U S A 2004; 101 Suppl 2:14622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/36\">",
"      Wildin RS, Freitas A. IPEX and FOXP3: clinical and research perspectives. J Autoimmun 2005; 25 Suppl:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/37\">",
"      Sabbah E, Savola K, Kulmala P, et al. Diabetes-associated autoantibodies in relation to clinical characteristics and natural course in children with newly diagnosed type 1 diabetes. The Childhood Diabetes In Finland Study Group. J Clin Endocrinol Metab 1999; 84:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/38\">",
"      Imagawa A, Hanafusa T, Miyagawa J, Matsuzawa Y. A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 2000; 342:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/39\">",
"      Boitard C. The differentiation of the immune system towards anti-islet autoimmunity. Clinical prospects. Diabetologia 1992; 35:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/40\">",
"      Nakayama M, Abiru N, Moriyama H, et al. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature 2005; 435:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/41\">",
"      Krishnamurthy B, Dudek NL, McKenzie MD, et al. Responses against islet antigens in NOD mice are prevented by tolerance to proinsulin but not IGRP. J Clin Invest 2006; 116:3258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/42\">",
"      Baekkeskov, S, Aanstoot, HJ, Christgau, S, et al. Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 1990; 347:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/43\">",
"      Pietropaolo M, Hutton JC, Eisenbarth GS. Protein tyrosine phosphatase-like proteins: link with IDDM. Diabetes Care 1997; 20:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/44\">",
"      Hawa M, Rowe R, Lan MS, et al. Value of antibodies to islet protein tyrosine phosphatase-like molecule in predicting type 1 diabetes. Diabetes 1997; 46:1270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/45\">",
"      Wenzlau JM, Juhl K, Yu L, et al. The cation efflux transporter ZnT8 (Slc30A8) is a major autoantigen in human type 1 diabetes. Proc Natl Acad Sci U S A 2007; 104:17040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/46\">",
"      Ziegler AG, Hillebrand B, Rabl W, et al. On the appearance of islet associated autoimmunity in offspring of diabetic mothers: a prospective study from birth. Diabetologia 1993; 36:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/47\">",
"      Achenbach P, Koczwara K, Knopff A, et al. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes. J Clin Invest 2004; 114:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/48\">",
"      Wong FS, Karttunen J, Dumont C, et al. Identification of an MHC class I-restricted autoantigen in type 1 diabetes by screening an organ-specific cDNA library. Nat Med 1999; 5:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/49\">",
"      Alleva DG, Crowe PD, Jin L, et al. A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin. J Clin Invest 2001; 107:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/50\">",
"      Moriyama H, Abiru N, Paronen J, et al. Evidence for a primary islet autoantigen (preproinsulin 1) for insulitis and diabetes in the nonobese diabetic mouse. Proc Natl Acad Sci U S A 2003; 100:10376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/51\">",
"      Bonifacio E, Atkinson M, Eisenbarth G, et al. International Workshop on Lessons From Animal Models for Human Type 1 Diabetes: identification of insulin but not glutamic acid decarboxylase or IA-2 as specific autoantigens of humoral autoimmunity in nonobese diabetic mice. Diabetes 2001; 50:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/52\">",
"      Bonifacio E, Atkinson M, Eisenbarth G, et al. International Workshop on Lessons from Animal Models for Human Type 1 Diabetes: analyzing target autoantigens of humoral immunity in nonobese diabetic mice. Ann N Y Acad Sci 2002; 958:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/53\">",
"      Jaeckel E, Klein L, Martin-Orozco N, von Boehmer H. Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase. J Exp Med 2003; 197:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/54\">",
"      Mziaut H, Trajkovski M, Kersting S, et al. Synergy of glucose and growth hormone signalling in islet cells through ICA512 and STAT5. Nat Cell Biol 2006; 8:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/55\">",
"      Ellis TM, Schatz DA, Ottendorfer EW, et al. The relationship between humoral and cellular immunity to IA-2 in IDDM. Diabetes 1998; 47:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/56\">",
"      Verge CF, Gianani R, Kawasaki E, et al. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies. Diabetes 1996; 45:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/57\">",
"      Wenzlau JM, Walter M, Gardner TJ, et al. Kinetics of the post-onset decline in zinc transporter 8 autoantibodies in type 1 diabetic human subjects. J Clin Endocrinol Metab 2010; 95:4712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/58\">",
"      Winer S, Tsui H, Lau A, et al. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med 2003; 9:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/59\">",
"      Pietropaolo M, Towns R, Eisenbarth GS. Humoral autoimmunity in type 1 diabetes: prediction, significance, and detection of distinct disease subtypes. Cold Spring Harb Perspect Med 2012; 2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/60\">",
"      Martin S, Wolf-Eichbaum D, Duinkerken G, et al. Development of type 1 diabetes despite severe hereditary B-lymphocyte deficiency. N Engl J Med 2001; 345:1036.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/61\">",
"      Yang M, Charlton B, Gautam AM. Development of insulitis and diabetes in B cell-deficient NOD mice. J Autoimmun 1997; 10:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/62\">",
"      Greeley SA, Katsumata M, Yu L, et al. Elimination of maternally transmitted autoantibodies prevents diabetes in nonobese diabetic mice. Nat Med 2002; 8:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/63\">",
"      Di Lorenzo TP, Peakman M, Roep BO. Translational mini-review series on type 1 diabetes: Systematic analysis of T cell epitopes in autoimmune diabetes. Clin Exp Immunol 2007; 148:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/64\">",
"      Peakman M, Stevens EJ, Lohmann T, et al. Naturally processed and presented epitopes of the islet cell autoantigen IA-2 eluted from HLA-DR4. J Clin Invest 1999; 104:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/65\">",
"      Allen JS, Pang K, Skowera A, et al. Plasmacytoid dendritic cells are proportionally expanded at diagnosis of type 1 diabetes and enhance islet autoantigen presentation to T-cells through immune complex capture. Diabetes 2009; 58:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/66\">",
"      Ko IY, Jun HS, Kim GS, Yoon JW. Studies on autoimmunity for initiation of beta-cell destruction. X. Delayed expression of a membrane-bound islet cell-specific 38 kDa autoantigen that precedes insulitis and diabetes in the diabetes-prone BB rat. Diabetologia 1994; 37:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/67\">",
"      Chong AS, Shen J, Tao J, et al. Reversal of diabetes in non-obese diabetic mice without spleen cell-derived beta cell regeneration. Science 2006; 311:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/68\">",
"      Nishio J, Gaglia JL, Turvey SE, et al. Islet recovery and reversal of murine type 1 diabetes in the absence of any infused spleen cell contribution. Science 2006; 311:1775.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/69\">",
"      Suri A, Calderon B, Esparza TJ, et al. Immunological reversal of autoimmune diabetes without hematopoietic replacement of beta cells. Science 2006; 311:1778.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/70\">",
"      Melton DA. Reversal of type 1 diabetes in mice. N Engl J Med 2006; 355:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/71\">",
"      Decochez K, Truyen I, van der Auwera B, et al. Combined positivity for HLA DQ2/DQ8 and IA-2 antibodies defines population at high risk of developing type 1 diabetes. Diabetologia 2005; 48:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/72\">",
"      Umpierrez GE, Latif KA, Murphy MB, et al. Thyroid dysfunction in patients with type 1 diabetes: a longitudinal study. Diabetes Care 2003; 26:1181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/73\">",
"      Brewer KW, Parziale VS, Eisenbarth GS. Screening patients with insulin-dependent diabetes mellitus for adrenal insufficiency. N Engl J Med 1997; 337:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/74\">",
"      Hoffenberg EJ, Emery LM, Barriga KJ, et al. Clinical features of children with screening-identified evidence of celiac disease. Pediatrics 2004; 113:1254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/75\">",
"      Jaeger C, Hatziagelaki E, Petzoldt R, Bretzel RG. Comparative analysis of organ-specific autoantibodies and celiac disease--associated antibodies in type 1 diabetic patients, their first-degree relatives, and healthy control subjects. Diabetes Care 2001; 24:27.",
"     </a>",
"    </li>",
"    <li>",
"     Barker, J, Eisenbarth GS. Autoimmune Polyendocrine Syndromes in Immunology of Type 1 Diabetes. Eienbarth GS, eds. 2003.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/77\">",
"      Vehik K, Hamman RF, Lezotte D, et al. Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth. Diabetes Care 2007; 30:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/78\">",
"      Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes 2002; 51:3353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/79\">",
"      Bach JF. The effect of infections on susceptibility to autoimmune and allergic diseases. N Engl J Med 2002; 347:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/80\">",
"      Redondo, MJ, Yu, L, Hawa, M, et al. Late progression to type 1 diabetes of discordant twins of patients with type 1 diabetes: Combined analysis of two twin series (United States and United Kingdom). Diabetes 1999; 48:780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/81\">",
"      Dahlquist GG, Patterson C, Soltesz G. Perinatal risk factors for childhood type 1 diabetes in Europe. The EURODIAB Substudy 2 Study Group. Diabetes Care 1999; 22:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/82\">",
"      Stene LC, Magnus P, Lie RT, et al. Birth weight and childhood onset type 1 diabetes: population based cohort study. BMJ 2001; 322:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/83\">",
"      Dahlquist GG, Pundzi��te-Lyck&aring; A, Nystr&ouml;m L, et al. Birthweight and risk of type 1 diabetes in children and young adults: a population-based register study. Diabetologia 2005; 48:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/84\">",
"      Stene LC, Joner G, Norwegian Childhood Diabetes Study Group. Use of cod liver oil during the first year of life is associated with lower risk of childhood-onset type 1 diabetes: a large, population-based, case-control study. Am J Clin Nutr 2003; 78:1128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/85\">",
"      Szopa TM, Titchener PA, Portwood ND, Taylor KW. Diabetes mellitus due to viruses--some recent developments. Diabetologia 1993; 36:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/86\">",
"      Yoon JW, Austin M, Onodera T, Notkins AL. Isolation of a virus from the pancreas of a child with diabetic ketoacidosis. N Engl J Med 1979; 300:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/87\">",
"      Foulis AK, McGill M, Farquharson MA, Hilton DA. A search for evidence of viral infection in pancreases of newly diagnosed patients with IDDM. Diabetologia 1997; 40:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/88\">",
"      Dotta F, Censini S, van Halteren AG, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci U S A 2007; 104:5115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/89\">",
"      King ML, Shaikh A, Bidwell D, et al. Coxsackie-B-virus-specific IgM responses in children with insulin-dependent (juvenile-onset; type I) diabetes mellitus. Lancet 1983; 1:1397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/90\">",
"      Hy&ouml;ty H, Hiltunen M, Knip M, et al. A prospective study of the role of coxsackie B and other enterovirus infections in the pathogenesis of IDDM. Childhood Diabetes in Finland (DiMe) Study Group. Diabetes 1995; 44:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/91\">",
"      Kaufman DL, Erlander MG, Clare-Salzler M, et al. Autoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitus. J Clin Invest 1992; 89:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/92\">",
"      Atkinson MA, Bowman MA, Campbell L, et al. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. J Clin Invest 1994; 94:2125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/93\">",
"      Menser MA, Forrest JM, Bransby RD. Rubella infection and diabetes mellitus. Lancet 1978; 1:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/94\">",
"      Hy&ouml;ty H, Taylor KW. The role of viruses in human diabetes. Diabetologia 2002; 45:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/95\">",
"      Zipris D, Lien E, Xie JX, et al. TLR activation synergizes with Kilham rat virus infection to induce diabetes in BBDR rats. J Immunol 2005; 174:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/96\">",
"      Devendra D, Jasinski J, Melanitou E, et al. Interferon-alpha as a mediator of polyinosinic:polycytidylic acid-induced type 1 diabetes. Diabetes 2005; 54:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/97\">",
"      Hummel M, F&uuml;chtenbusch M, Schenker M, Ziegler AG. No major association of breast-feeding, vaccinations, and childhood viral diseases with early islet autoimmunity in the German BABYDIAB Study. Diabetes Care 2000; 23:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/98\">",
"      Cainelli F, Manzaroli D, Renzini C, et al. Coxsackie B virus-induced autoimmunity to GAD does not lead to type 1 diabetes. Diabetes Care 2000; 23:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/99\">",
"      Dyrberg T, Schwimmbeck PL, Oldstone MB. Inhibition of diabetes in BB rats by virus infection. J Clin Invest 1988; 81:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/100\">",
"      Oldstone MB. Prevention of type I diabetes in nonobese diabetic mice by virus infection. Science 1988; 239:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/101\">",
"      Like AA, Guberski DL, Butler L. Influence of environmental viral agents on frequency and tempo of diabetes mellitus in BB/Wor rats. Diabetes 1991; 40:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/102\">",
"      Hviid A, Stellfeld M, Wohlfahrt J, Melbye M. Childhood vaccination and type 1 diabetes. N Engl J Med 2004; 350:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/103\">",
"      Yoon JW. The role of viruses and environmental factors in the induction of diabetes. Curr Top Microbiol Immunol 1990; 164:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/104\">",
"      Virtanen SM, Saukkonen T, Savilahti E, et al. Diet, cow's milk protein antibodies and the risk of IDDM in Finnish children. Childhood Diabetes in Finland Study Group. Diabetologia 1994; 37:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/105\">",
"      Norris JM, Beaty B, Klingensmith G, et al. Lack of association between early exposure to cow's milk protein and beta-cell autoimmunity. Diabetes Autoimmunity Study in the Young (DAISY). JAMA 1996; 276:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/106\">",
"      Couper JJ, Steele C, Beresford S, et al. Lack of association between duration of breast-feeding or introduction of cow's milk and development of islet autoimmunity. Diabetes 1999; 48:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/107\">",
"      Cavallo MG, Fava D, Monetini L, et al. Cell-mediated immune response to beta casein in recent-onset insulin-dependent diabetes: implications for disease pathogenesis. Lancet 1996; 348:926.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/108\">",
"      Elliott RB, Harris DP, Hill JP, et al. Type I (insulin-dependent) diabetes mellitus and cow milk: casein variant consumption. Diabetologia 1999; 42:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/109\">",
"      Norris JM, Barriga K, Klingensmith G, et al. Timing of initial cereal exposure in infancy and risk of islet autoimmunity. JAMA 2003; 290:1713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/110\">",
"      Ziegler AG, Schmid S, Huber D, et al. Early infant feeding and risk of developing type 1 diabetes-associated autoantibodies. JAMA 2003; 290:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/111\">",
"      Norris JM, Barriga K, Hoffenberg EJ, et al. Risk of celiac disease autoimmunity and timing of gluten introduction in the diet of infants at increased risk of disease. JAMA 2005; 293:2343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/112\">",
"      Krishna Mohan I, Das UN. Prevention of chemically induced diabetes mellitus in experimental animals by polyunsaturated fatty acids. Nutrition 2001; 17:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/113\">",
"      Kleemann R, Scott FW, W&ouml;rz-Pagenstert U, et al. Impact of dietary fat on Th1/Th2 cytokine gene expression in the pancreas and gut of diabetes-prone BB rats. J Autoimmun 1998; 11:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/114\">",
"      Norris JM, Yin X, Lamb MM, et al. Omega-3 polyunsaturated fatty acid intake and islet autoimmunity in children at increased risk for type 1 diabetes. JAMA 2007; 298:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/115\">",
"      Parslow RC, McKinney PA, Law GR, et al. Incidence of childhood diabetes mellitus in Yorkshire, northern England, is associated with nitrate in drinking water: an ecological analysis. Diabetologia 1997; 40:550.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/116\">",
"      McCulloch DK, Palmer JP, Benson EA. Beta cell function in the preclinical period of insulin-dependent diabetes. Diabetes Metab Rev 1987; 3:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/117\">",
"      Thai, AC, Eisenbarth, GS. Natural history of IDDM. Diabetes Reviews 1993; 1:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/118\">",
"      Sosenko JM, Palmer JP, Greenbaum CJ, et al. Increasing the accuracy of oral glucose tolerance testing and extending its application to individuals with normal glucose tolerance for the prediction of type 1 diabetes: the Diabetes Prevention Trial-Type 1. Diabetes Care 2007; 30:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/119\">",
"      Bingley PJ, Colman P, Eisenbarth GS, et al. Standardization of IVGTT to predict IDDM. Diabetes Care 1992; 15:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/120\">",
"      McCulloch DK, Bingley PJ, Colman PG, et al. Comparison of bolus and infusion protocols for determining acute insulin response to intravenous glucose in normal humans. The ICARUS Group. Islet Cell Antibody Register User's Study. Diabetes Care 1993; 16:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/121\">",
"      McCulloch DK, Koerker DJ, Kahn SE, et al. Correlations of in vivo beta-cell function tests with beta-cell mass and pancreatic insulin content in streptozocin-administered baboons. Diabetes 1991; 40:673.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/122\">",
"      Strandell E, Eizirik DL, Sandler S. Reversal of beta-cell suppression in vitro in pancreatic islets isolated from nonobese diabetic mice during the phase preceding insulin-dependent diabetes mellitus. J Clin Invest 1990; 85:1944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/123\">",
"      Conget I, Fern&aacute;ndez-Alvarez J, Ferrer J, et al. Human pancreatic islet function at the onset of type 1 (insulin-dependent) diabetes mellitus. Diabetologia 1993; 36:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/124\">",
"      Nir T, Melton DA, Dor Y. Recovery from diabetes in mice by beta cell regeneration. J Clin Invest 2007; 117:2553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/125\">",
"      George M, Ayuso E, Casellas A, et al. Beta cell expression of IGF-I leads to recovery from type 1 diabetes. J Clin Invest 2002; 109:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?22/42/23210/abstract/126\">",
"      Kulkarni RN, Holzenberger M, Shih DQ, et al. beta-cell-specific deletion of the Igf1 receptor leads to hyperinsulinemia and glucose intolerance but does not alter beta-cell mass. Nat Genet 2002; 31:111.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1800 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-894C5EFDCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23210=[""].join("\n");
var outline_f22_42_23210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H28\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENETIC SUSCEPTIBILITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MHC genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Non-MHC genes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      AUTOIMMUNITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Target autoantigens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Insulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Glutamic acid decarboxylase",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Insulinoma-associated protein 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Zinc transporter ZnT8",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H414416\">",
"      - Other type 1 diabetes-related autoantigens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Role of cellular immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Molecular mimicry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Reversal of diabetes in animal models",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Association with other autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      ENVIRONMENTAL FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Perinatal factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Role of viruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Childhood immunization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Role of diet",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Cow's milk",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Vitamin D supplements",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Cereals",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Omega-3 fatty acids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Nitrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      DETERMINANTS OF INSULIN DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      CLINICAL RESEARCH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8088213\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1800\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1800|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?20/12/20686\" title=\"figure 1\">",
"      Course of IDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/23/6527\" title=\"figure 2\">",
"      Antigen presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/47/29437\" title=\"figure 3\">",
"      Diabetogenic genes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/10/28845\" title=\"figure 4\">",
"      Insulin secretion in NOD mouse",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1800|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/13/219\" title=\"table 1\">",
"      Confirmed targets autoantibodies T1 DM",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/43/31414?source=related_link\">",
"      Associated autoimmune diseases in children and adolescents with type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26857?source=related_link\">",
"      Autism and chronic disease: Little evidence for vaccines as a contributing factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/33/14874?source=related_link\">",
"      Classification of diabetes mellitus and genetic diabetic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/2/14377?source=related_link\">",
"      Diagnosis of celiac disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/34/2601?source=related_link\">",
"      Dietary fat",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/59/40889?source=related_link\">",
"      Epidemiology, presentation, and diagnosis of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/43/10938?source=related_link\">",
"      Introducing solid foods and vitamin and mineral supplementation during infancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/41/27283?source=related_link\">",
"      Major histocompatibility complex (MHC) structure and function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/9/40090?source=related_link\">",
"      Management of type 1 diabetes mellitus in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/57/3992?source=related_link\">",
"      Overview of autoimmunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/42/9896?source=related_link\">",
"      Pathogenesis of autoimmune adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/31/36346?source=related_link\">",
"      Pathogenesis of type 2 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/44/40650?source=related_link\">",
"      Pathogenesis, epidemiology, and clinical manifestations of celiac disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/26/36259?source=related_link\">",
"      Patient information: Diabetes mellitus type 1: Overview (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/43/692?source=related_link\">",
"      Patient information: Type 1 diabetes (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/21/32087?source=related_link\">",
"      Prediction of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/5/13401?source=related_link\">",
"      Prevention of type 1 diabetes mellitus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f22_42_23211="Characteristics of RTA";
var content_f22_42_23211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58428&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Characteristics of the different types of renal tubular acidosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 1 RTA",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 2 RTA",
"       </td>",
"       <td class=\"subtitle1\">",
"        Type 4 RTA",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Primary defect",
"       </td>",
"       <td>",
"        Impaired distal acidification",
"       </td>",
"       <td>",
"        Reduced proximal bicarbonate reabsorption",
"       </td>",
"       <td>",
"        Decreased aldosterone secretion or effect",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma bicarbonate",
"       </td>",
"       <td>",
"        Variable, may be below 10 meq/L",
"       </td>",
"       <td>",
"        Usually 12 to 20 meq/L",
"       </td>",
"       <td>",
"        Greater than 17 meq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine pH",
"       </td>",
"       <td>",
"        Greater than 5.3",
"       </td>",
"       <td>",
"        Variable, greater than 5.3 if above bicarbonate reabsorptive threshold",
"       </td>",
"       <td>",
"        Usually less than 5.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plasma potassium",
"       </td>",
"       <td>",
"        Usually reduced but hyperkalemic forms exist; hypokalemia largely corrects with alkali therapy",
"       </td>",
"       <td>",
"        Reduced, made worse by bicarbonaturia induced by alkali therapy",
"       </td>",
"       <td>",
"        Increased",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23211=[""].join("\n");
var outline_f22_42_23211=null;
var title_f22_42_23212="Nutrition assessment premature";
var content_f22_42_23212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53587&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Nutritional assessment of the enterally fed premature infant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Assessment",
"       </td>",
"       <td class=\"subtitle1\">",
"        Frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Fluid intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Parenteral",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Enteral",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Nutrient intake",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Energy",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Protein",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Specific nutrient",
"       </td>",
"       <td>",
"        Daily",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Anthropomorphic measurements",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Body weight",
"       </td>",
"       <td>",
"        Daily at same time",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Length",
"       </td>",
"       <td>",
"        Weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Head circumference",
"       </td>",
"       <td>",
"        Weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\" rowspan=\"1\">",
"        Laboratory values",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hemoglobin, hematocrit",
"       </td>",
"       <td>",
"        Weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Reticulocyte count",
"       </td>",
"       <td>",
"        Weekly",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Serum electrolytes",
"       </td>",
"       <td>",
"        Weekly twice, then every other week if receiving human milk or diuretics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium, phosphorus",
"       </td>",
"       <td>",
"        Weekly twice, then every other week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alkaline phosphatase",
"       </td>",
"       <td>",
"        Weekly twice, then every other week",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Albumin, BUN",
"       </td>",
"       <td>",
"        Weekly twice, then every other week; if values are abnormal, also measure prealbumin",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Schanler RJ. The low birth weight infant: Perinatal nutrition. In: Nutrition in Pediatrics: Basic Science and Clinical Applications, Walker WA, Watkins JB (Eds), B.C. Decker Inc., Hamilton, Ontario, Canada 1996. p. 387.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23212=[""].join("\n");
var outline_f22_42_23212=null;
var title_f22_42_23213="Differential dx of low back pain";
var content_f22_42_23213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F60679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F60679&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Differential diagnosis of low back pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Mechanical low back pain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Lumbar strain",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Degenerative disease",
"            <br/>",
"            <ul>",
"             <li>",
"              Discs (spondylosis)",
"             </li>",
"             <li>",
"              Facet joints",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spondylolisthesis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Herniated disc",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Spinal stenosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Osteoporosis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fractures",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Congenital disease",
"            <br/>",
"            <ul>",
"             <li>",
"              Severe kyphosis",
"             </li>",
"             <li>",
"              Severe scoliosis",
"             </li>",
"             <li>",
"              Possible type II transitional vertebra*",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Possible spondylolysis",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Possible facet joint asymmetry",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Non-mechanical spine disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Neoplasia",
"            <br/>",
"            <ul>",
"             <li>",
"              Multiple myeloma",
"             </li>",
"             <li>",
"              Metastatic carcinoma",
"             </li>",
"             <li>",
"              Lymphoma and leukemia",
"             </li>",
"             <li>",
"              Spinal cord tumors",
"             </li>",
"             <li>",
"              Retroperitoneal tumors",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Infection",
"            <br/>",
"            <ul>",
"             <li>",
"              Osteomyelitis",
"             </li>",
"             <li>",
"              Septic discitis",
"             </li>",
"             <li>",
"              Paraspinous abscess",
"             </li>",
"             <li>",
"              Epidural abscess",
"             </li>",
"             <li>",
"              Bacterial endocarditis",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Inflammatory arthritis (often HLA-B27 associated)",
"            <br/>",
"            <ul>",
"             <li>",
"              Ankylosing spondylitis",
"             </li>",
"             <li>",
"              Psoriatic spondylitis",
"             </li>",
"             <li>",
"              Reiter's syndrome",
"             </li>",
"             <li>",
"              Inflammatory bowel disease",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Scheuermann's disease (osteochondrosis)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Paget's disease",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1\">",
"            Visceral disease",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Pelvic organs",
"            <br/>",
"            <ul>",
"             <li>",
"              Prostatitis",
"             </li>",
"             <li>",
"              Endometriosis",
"             </li>",
"             <li>",
"              Chronic pelvic inflammatory disease",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Renal disease",
"            <br/>",
"            <ul>",
"             <li>",
"              Nephrolithiasis",
"             </li>",
"             <li>",
"              Pyelonephritis",
"             </li>",
"             <li>",
"              Perinephric abscess",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Aortic aneurysm",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Gastrointestinal disease",
"            <br/>",
"            <ul>",
"             <li>",
"              Pancreatitis",
"             </li>",
"             <li>",
"              Cholecystitis",
"             </li>",
"             <li>",
"              Penetrating ulcer",
"             </li>",
"            </ul>",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Fat herniation of lumbar space",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * A transitional vertebra is a congenital anomaly in which there is a naturally occurring articulation or bony fusion between the transverse processes of L5 and the sacrum, but there is still a small remnant disc space between L5 and sacrum. Type II means that one or both transverse processes appear to form a diarthrodial joint with the sacrum, but there is no bony fusion.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Deyo RA. Early diagnostic evaluation of low back pain. J Gen Intern Med 1986; 1:328, with kind permission from Springer Science + Business Media B.V. Copyright &copy; 1986.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23213=[""].join("\n");
var outline_f22_42_23213=null;
var title_f22_42_23214="Contents: Immunology basic science";
var content_f22_42_23214=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?39/57/40861\">",
"       Hematology",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Immunology basic science",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Immunology basic science",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Cell biology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/37/16986\">",
"           An overview of the innate immune system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/49/22293\">",
"           Peptide hormone signal transduction and regulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/54/13159\">",
"           Polymerase chain reaction",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cellular immunity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/53/25432\">",
"           Antigen presenting cells",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/38/5735\">",
"           Apoptosis and autoimmune disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17048\">",
"           Determinants of neutrophil movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/22/36201\">",
"           Immunology of the maternal-fetal interface",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/54/36711\">",
"           Leukocyte-endothelial adhesion in the pathogenesis of inflammation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/6/34921\">",
"           Mast cell derived mediators",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/22/44393\">",
"           Mast cells: Development, identification, and physiologic roles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/28/20936\">",
"           Mast cells: Surface receptors and signal transduction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/31/6650\">",
"           Neutrophil functions other than movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/23/31098\">",
"           Normal B and T lymphocyte development",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/2/6185\">",
"           Normal neutrophil development and kinetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/54/37733\">",
"           T cell receptor genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/58/41897\">",
"           T helper subsets: Differentiation and role in disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/58/6056\">",
"           The adaptive cellular immune response",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/54/23401\">",
"           Toll-like receptors: Roles in disease and therapy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Complement",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/59/11190\">",
"           Complement pathways",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/58/42920\">",
"           Inherited disorders of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/25/10647\">",
"           Overview and clinical assessment of the complement system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/38/10854\">",
"           Regulators and receptors of the complement system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cytokines and inflammation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/42/38569\">",
"           Acute phase reactants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/22/16746\">",
"           Cytokine networks in rheumatic diseases: Implications for therapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/37/28249\">",
"           Glucocorticoid effects on the immune system",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/57/3992\">",
"           Overview of autoimmunity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/50/10025\">",
"           Role of cytokines in rheumatic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/8/4231\">",
"           Role of cytokines in the immune system",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         HLA",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/63/23546\">",
"           HLA and other susceptibility genes in rheumatoid arthritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/38/24167\">",
"           Human leukocyte antigens (HLA): A roadmap",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/41/27283\">",
"           Major histocompatibility complex (MHC) structure and function",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Humoral immunity",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/53/40792\">",
"           Function and clinical applications of immunoglobulins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/52/37702\">",
"           Immunoglobulin genetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/9/7318\">",
"           Structure of immunoglobulins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/62/27624\">",
"           The humoral immune response",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Transplantation immunology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/43/44729\">",
"           Biology of the graft-versus-tumor effect following hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/51/33590\">",
"           Gene therapy for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/2/1066\">",
"           Hematopoietic cell transplantation for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/24/18826\">",
"           Pathogenesis of graft-versus-host disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/27/10682\">",
"           Transplantation immunobiology",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-246981A241-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f22_42_23214=[""].join("\n");
var outline_f22_42_23214=null;
var title_f22_42_23215="Side leg raise exercise";
var content_f22_42_23215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F72859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F72859&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Strength exercise: Side leg raise",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise strengthens hips, thighs, and buttocks. For an added challenge, you can modify the exercise to improve your balance.",
"    <ol>",
"     <li>",
"      Stand behind a sturdy chair with feet slightly apart, holding on for balance. Breathe in slowly.",
"     </li>",
"     <li>",
"      Breathe out and slowly lift one leg out to the side. Keep your back straight and your toes facing forward. The leg you are standing on should be slightly bent.",
"     </li>",
"     <li>",
"      Hold position for one second.",
"     </li>",
"     <li>",
"      Breathe in as you slowly lower your leg.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 times.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 times with other leg.",
"     </li>",
"     <li>",
"      Repeat 10 to 15 more times with each leg.",
"     </li>",
"    </ol>",
"    As you progress, you may want to add ankle weights.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f22_42_23215=[""].join("\n");
var outline_f22_42_23215=null;
